tag:blogger.com,1999:blog-87829642808905014992023-11-15T23:20:48.028-08:00Healthcare Market Insights | Industry ReportMr. Rohit Chavanhttp://www.blogger.com/profile/08706042746893719666noreply@blogger.comBlogger115125tag:blogger.com,1999:blog-8782964280890501499.post-91840025401312012932020-11-06T06:48:00.004-08:002020-11-06T06:49:53.834-08:00Refurbished Medical Imaging Equipment Market Worth $21.14 Billion By 2027 | Polaris Market Research<p style="text-align: justify;"><b>New York City, 6 Nov 2020: </b>The global <a href="https://www.polarismarketresearch.com/industry-analysis/refurbished-medical-imaging-equipment-market"><b>refurbished medical imaging equipment market</b></a> size is expected to reach USD 21.14 billion by 2027 according to a new study by Polaris Market Research. Refurbished equipment is second hand old equipment restoring the devices to original condition without damage to the specifications. The safety and effectiveness of the refurbished equipment is comparable to new devices. In refurbishment process the equipment will undergo changes like decontamination, calibration, repair, software upgrade, cosmetic rehabilitation, replacement of worn parts, and other procedures to match to original OEM specifications.</p><p style="text-align: justify;">The OEM refurbished equipment is good alternative to new products, as these systems undergo complete set of industrial procedures and available with high quality, lower price and manufacturer warranty. Hence, adoption of refurbished products helps hospitals and diagnostics centres to reduce the investments on infrastructure.</p><table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto;"><tbody><tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjmZ3PLtB2aekbcO7qaSvE5BLx8beqVwZTA57tydSTpHfvfcI5iQUUV3SaCcISsEoChwwxsW-hjrg_bxpfWJVU-I5LG6OKEXljWwhTkrDLTrJIpXXMHPO1iAH89wrAYTdZHpfO6el-Mnbw/s876/Refurbished-Medical-Imaging-Equipment-Market.png" style="margin-left: auto; margin-right: auto;"><img border="0" data-original-height="323" data-original-width="876" height="148" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjmZ3PLtB2aekbcO7qaSvE5BLx8beqVwZTA57tydSTpHfvfcI5iQUUV3SaCcISsEoChwwxsW-hjrg_bxpfWJVU-I5LG6OKEXljWwhTkrDLTrJIpXXMHPO1iAH89wrAYTdZHpfO6el-Mnbw/w400-h148/Refurbished-Medical-Imaging-Equipment-Market.png" width="400" /></a></td></tr><tr><td class="tr-caption" style="text-align: center;"><a href="https://www.polarismarketresearch.com/industry-analysis/refurbished-medical-imaging-equipment-market/request-for-sample"><b> Request for sample pages</b></a><br /><br /></td></tr></tbody></table><span style="text-align: justify;"><br /></span><div><div style="text-align: left;"><span style="text-align: justify;">The refurbished medical imaging equipment is cost-effective which can be bought for as low as 30% to 70% of the original equipment cost. The cost of these second hand devices, depending on features, age of the system and the condition. By purchasing refurbished equipment, the hospitals can upgrade their imaging capability at the lower cost.</span></div><p style="text-align: justify;"></p><div style="text-align: justify;">The market growth is primarily attributed to increasing demand for cost-effective medical imaging equipment, increasing adoption of refurbished equipment in private healthcare sector, tax incentives, extended service life of refurbished equipment and growing e commerce. There is an increasing demand for low cost medical imaging equipment by small and mid-level hospitals, diagnostic centres and private medical institutions due to lack of enough financial resources.</div><p></p><p style="text-align: justify;">Emerging and low income countries are the lucrative target destination for the concerned market. In India, district, municipal and less sophisticated hospitals often go for used medical devices due to budget constraints. Indian hospitals demand continuous service back-up for instruments and the spare parts being sold and international companies need to have liaison offices in the country to promote the sale of these devices.</p><p style="text-align: justify;"><b>Market participants such as </b>GE Healthcare, Siemens Healthineers, Koninklijke Philips N.V., Block Imaging, SOMA TECH INTL., US Med-Equip, Avante Health Solutions, Everx Pvt Ltd., Integrity Medical Systems, Inc., Radiology Oncology Systems, Inc., Master Medical Equipment, Hilditch Group, Fair Medical Co. Ltd., Future Health Concepts, US Medical Systems, LLC., Nationwide Imaging Services, Pacific Healthcare Imaging, LLC, Venture Medical ReQuip, Inc., Desert Tech Medical Systems, and Hi Tech International Group, Inc. are operating in the concerned market.</p><p style="text-align: justify;">The companies in the market are focussing on acquisitions to increase their market share. For instance, recently in February 2020, the U.S., based supplier of refurbished medical equipment Probo Medical, announced the acquisition of Elite Medical Technologies, LLC and Future Medical Equipment, Ltd. The former is the renowned re-seller of the pre-owned digital medical devices, while the latter is specialized in de-installation and sales of second hand equipment. </p><p style="text-align: justify;"><b style="text-align: left;">Get To Know More @ <a href="https://www.polarismarketresearch.com/industry-analysis/refurbished-medical-imaging-equipment-market">https://www.polarismarketresearch.com/industry-analysis/refurbished-medical-imaging-equipment-market</a></b></p></div>Mr. Rohit Chavanhttp://www.blogger.com/profile/08706042746893719666noreply@blogger.com0tag:blogger.com,1999:blog-8782964280890501499.post-23766018066858424972020-11-06T06:44:00.003-08:002020-11-06T06:44:28.333-08:00Medical Drones Market To Reach US$ 947.6 Million By 2027 | CAGR: 31.6% | PMR<p style="text-align: justify;"><b>New York City, 6 Nov 2020: </b>The global <a href="https://www.polarismarketresearch.com/industry-analysis/medical-drones-market"><b>medical drones market</b></a> size is expected to reach <b>USD 947.6 million by 2027 </b>according to a new study by Polaris Market Research. Medical drones refer to the aerodynamic pods that are being deployed to transport key medical supplies that comprises of primary medical aids, vaccines, and drugs. Through the development of highly advanced technology has resulted in notable adoption of medical drones across the hospitals and military bases.</p><p style="text-align: justify;">There’s continuous ongoing research in this field to develop new products with superior accuracy and speed in delivery of medical supplies to the targeted location. These drones can be either operated manually or they can be strategically programmed for performing long-distance flights and following the designated route precisely. In addition, they also have several key benefits such as they don’t require any landing space and can be programmed to drop the supplies by flying near to the ground.</p><table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto;"><tbody><tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEilWo-eJfas3FP7hWAf6ex_LmvPX7uj6WKqHa7e3XP66ALt4qYu-8INBZ0oj9Gl7Tl9Ik-00sLd9u98DYcLZSUWQp6zKoZ61ZkxuFXG22-h6X_emxrSfT9eDoFr5ezos6CAOYMG7W5Z_YE/s788/Medical-Drones-Market.png" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" data-original-height="329" data-original-width="788" height="168" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEilWo-eJfas3FP7hWAf6ex_LmvPX7uj6WKqHa7e3XP66ALt4qYu-8INBZ0oj9Gl7Tl9Ik-00sLd9u98DYcLZSUWQp6zKoZ61ZkxuFXG22-h6X_emxrSfT9eDoFr5ezos6CAOYMG7W5Z_YE/w400-h168/Medical-Drones-Market.png" width="400" /></a></td></tr><tr><td class="tr-caption" style="text-align: center;"><a href="https://www.polarismarketresearch.com/industry-analysis/medical-drones-market/request-for-sample"><b>Request for sample pages</b></a></td></tr></tbody></table><br /><p style="text-align: justify;">Further, the impressive capability of these drones to make a flight over the closed zones and that too without any requirement of crew is the key reason for their high demand. Some other major benefits include, transporting blood samples or other lab samples to remote and small hospitals and clinics; medical support or telemedicine including, drugs, diagnostics, or key medical tools that include, portable ultrasound to remote locations or tough military terrain.</p><p style="text-align: justify;">Apart from this, this technology also offer benefits such as medical supplies that include, anti-venom or vaccines to the disease exposed or disaster relief regions, providing medical supplies and prescriptions to people who are hard to reach such as those at home or at sea. Moreover, providing defibrillators to patients suffering from cardiac arrest and offering organs required for transplantation are some major applications of medical drones.</p><p style="text-align: justify;"><b>Market participants such as</b> Zipline, DJI, DHL, TUDelft, Flirtey, Embention, Matternet, Vayu, and EHang are some of the key players operating in the global market. Zipline drones, the frontrunner in the market, have cumulatively flown more than 1 million kilometres in Rwanda with more than 13 thousand deliveries. In the outskirts of Kigali, drones carried 35% of blood samples to be transfused. The Ghana the company is also started delivering COVID-19 testing kits.</p><p style="text-align: justify;">Players in the market have primarily adopted partnership strategy to strengthen their position in the global market. For instance, in June 2020, TechEagle has partnered with Zomato to boost the delivery of medical supplies via drones all across the regions in India that are facing floods and due to the ongoing <b>COVID-19 pandemic situation.</b></p><p style="text-align: justify;">The UK based research firm Nesta in its report titled “Flying High” in collaboration with NHS discussed the possibilities of rapid transportation of medical necessities in between the UK hospitals based in London. This move could bring faster delivery, reliable cost cutting, and improved timely patient care, even to the accident areas. It is being estimated that the use of medical drones could result in saving USD 21 billion in the annual cost to the country’s economy.</p><p style="text-align: left;"><b>Get To Know More @ <a href="https://www.polarismarketresearch.com/industry-analysis/medical-drones-market">https://www.polarismarketresearch.com/industry-analysis/medical-drones-market</a></b></p>Mr. Rohit Chavanhttp://www.blogger.com/profile/08706042746893719666noreply@blogger.com0tag:blogger.com,1999:blog-8782964280890501499.post-80003341823701280822020-11-06T06:38:00.001-08:002020-11-06T06:38:56.229-08:00Telepharmacy Market To Reach US$ 71.43 billion by 2027 | Polaris Market Research<p style="text-align: justify;"><b>New York City, 6 Nov 2020:</b> The global <a href="https://www.polarismarketresearch.com/industry-analysis/telepharmacy-market"><b>telepharmacy market</b></a> size is expected to reach <b>USD 71.43 billion by 2027 </b>according to a new study by Polaris Market Research. Telepharmacy refers to the process of delivering the pharmaceutical care through telecommunications to the patients across various locations where getting consultation from any healthcare professional is next to impossible. Telepharmacy is a subset of telemedicine which is a wider term used by the healthcare experts.</p><p style="text-align: justify;">Certain services involved in telepharmacy includes patient counselling, drug therapy monitoring, refill authorization and prior authorization needed for the prescription drugs. Other telepharmacy services comprises of monitoring the formulary compliance through the deployment of videoconferencing or teleconferencing. Telepharmacy may also involve remote delivery of medicines through automated labelling and packaging systems. In addition, the delivery of telepharmacy services may even be performed through the assistance of healthcare facilities such as nursing homes, hospitals or other healthcare institutions. Telepharmacy may also deploy videoconferencing technique across the pharmacy in order to provide management, training and education services to pharmacy staff and pharmacists remotely.</p><table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto;"><tbody><tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi4PvPGZcD9utr0mT0GI5fq1IaJGYnFszthKpxaWYddd1odCJlPffMmjKCYk2ChyphenhyphenJSGMy3XwttHxzOrzMi3KE07G8kb_YQeEuE0sp9qHJTnnvSNxu71p3aJqSG8lEZjnbAIDbmPqJ7xPbs/s830/Telepharmacy-Market-Size.png" style="margin-left: auto; margin-right: auto;"><img border="0" data-original-height="323" data-original-width="830" height="156" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi4PvPGZcD9utr0mT0GI5fq1IaJGYnFszthKpxaWYddd1odCJlPffMmjKCYk2ChyphenhyphenJSGMy3XwttHxzOrzMi3KE07G8kb_YQeEuE0sp9qHJTnnvSNxu71p3aJqSG8lEZjnbAIDbmPqJ7xPbs/w400-h156/Telepharmacy-Market-Size.png" width="400" /></a></td></tr><tr><td class="tr-caption" style="text-align: center;"> <a href="https://www.polarismarketresearch.com/industry-analysis/telepharmacy-market/request-for-sample"><b>Request for sample pages</b></a></td></tr></tbody></table><p style="text-align: justify;">The prominent factors favoring the global market growth include advancement in technology, substantial investments in telepharmacy and rise in the prevalence of diseases. Telepharmacy offers medical care at minimal costs to the rural and other backward regions worldwide. For instance, the advancements in telehealth technology that includes faxes, videoconferencing, electronic healthcare information gathering techniques including, electronic health record (EHR).</p><p style="text-align: justify;">These key technologies allow the pharmacists to proactively contribute novel and unique ways to enhance the usage of medicines in healthcare settings that include, hospitals, community pharmacy locations, nursing home as well as various other healthcare facilities. Moreover, the rising internet penetration worldwide has resulted in increasing preference for online healthcare services. Furthermore, the ongoing COVID-19 pandemic worldwide has driven the demand for maintaining social distancing amid lockdown which has in turn fueled the demand for online healthcare services that’s also anticipated to contribute to market growth. </p><p style="text-align: justify;">There’s significant variation in the implementation practices for telepharmacy depending on the region for implementation and its jurisdiction. Some key factors that include, economics, regulations and laws coupled with geography highly influence the implementation of telepharmacy. United States, Australia, Canada, Venezuela, Spain, Japan, Italy, Guam, Germany, England, Cuba, Belgium, and Bahrain are some of the nations that have deployed remote and automatic medical supply dispensing machines. Also, patients are being provided with medicines at the pharmacy outlets through the use of videoconferencing and that too without any requirement of a full-time pharmacist. </p><p style="text-align: justify;"><b>Market participants such as</b> Medication Review, Inc., North West TelePharmacy Solutions, McKesson Ventures, Pipeline Health Holdings, Mitsui & Co., Inc., MedTel Services, TelePharm, LLC, One Touch Telehealth, Comprehensive Pharmacy Services, Inc., AMN Healthcare, and Telepharmacy Solutions, Inc. are some of the key players operating in the global market. </p><p style="text-align: justify;">Players in the market are focusing on strategic partnership with other key companies to strengthen their market position across the globe. For instance, in June 2019, Pipeline Health Holdings which is a telepharmacy company has entered into a partnership agreement with YouScript Incorporated in order to provide highly-personalized prescribing software tools across its advanced platform referred to as PowerGridRx. This strategic partnership agreement is anticipated to enhance patient results through providing safe and optimal medical aid to each patient. PowerGridRx platform comprising of personalized prescribing software tools is combined with EHRs can simply offer key services to healthcare institutions such as hospitals, clinics, ambulatory surgical centers (ASCs) and other key healthcare facilities.</p><p style="text-align: justify;"><b>Get To Know More @ <a href="https://www.polarismarketresearch.com/industry-analysis/telepharmacy-market">https://www.polarismarketresearch.com/industry-analysis/telepharmacy-market</a></b></p>Mr. Rohit Chavanhttp://www.blogger.com/profile/08706042746893719666noreply@blogger.com0tag:blogger.com,1999:blog-8782964280890501499.post-3839352284489403882020-11-06T04:49:00.006-08:002020-11-06T05:35:56.631-08:00Cancer/Tumor Profiling Market to Surpass $15.32 Billion By 2027 | CAGR: 7.15% | PMR<p style="text-align: justify;"><b>New York City, 6 Nov 2020: </b>The global <a href="https://www.polarismarketresearch.com/industry-analysis/cancer-tumor-profiling-market"><b>cancer/tumor profiling market</b></a> size is expected to reach USD 15.32 billion by 2027 according to a new study by Polaris Market Research. The report “<b><i>Cancer/Tumor Profiling Market Share, Size, Trends, Industry Analysis Report by Technology (Immunoassay, NGS, PCR, In Situ Hybridization, Microarray, Mass Spectrometry, Others); By Cancer Type (Breast, Lung, Colorectal, Prostate, Melanoma, Others); By Biomarker Type (Genomic Biomarkers, Protein Biomarkers, Others); By Application (Personalized Medicine, Diagnostics, Prognostics, Biomarker Discovery, Research); By Regions – Segment – Forecast, 2020 – 2027</i></b>” gives a detailed insight into current market dynamics and provides analysis on future market growth.</p><p style="text-align: justify;">Increasing demand for tumor profiling and diagnosis and therapy techniques is driven by oncologists. Increased use of biomarkers in tumor profiling and increasing use of next-generation cancer profiling sequencing methods are some of the main factors driving the growth of the tumor profiling market. Tumor profiling is used to evaluate the metabolism, properties, and mutations of the tumor that can assist discover effective therapies. Drugs that target these mutated kinases can be discovered and developed based on genetic modification. The profiling is considered a requirement to increase the sensitivity of kinases-focused medications because they rely on individual tumors genetic composition. Thus, these mutated profiles of DNA tumors help to create specific anticarcinogenic treatments.</p><table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto;"><tbody><tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhODYHOKfqaPEQeW5KsvucScfAIqjf4pKXQP-tqBmSV1xrb-NW53qyBOJgGBBZWAFDgnyQzd5EcW9t0WBggScctb6gQ_IE_gMBhJW8pK47N-57mixPePSWl-upTKKTTiiqAy0d0Qz-Inp4/s609/Tumor-Profiling-Market.png" style="margin-left: auto; margin-right: auto;"><img border="0" data-original-height="290" data-original-width="609" height="190" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhODYHOKfqaPEQeW5KsvucScfAIqjf4pKXQP-tqBmSV1xrb-NW53qyBOJgGBBZWAFDgnyQzd5EcW9t0WBggScctb6gQ_IE_gMBhJW8pK47N-57mixPePSWl-upTKKTTiiqAy0d0Qz-Inp4/w400-h190/Tumor-Profiling-Market.png" width="400" /></a></td></tr><tr><td class="tr-caption" style="text-align: center;"><span face="Roboto, sans-serif" style="background-color: white; font-size: 15px;">Know more about this report: </span><span style="background-color: white; box-sizing: border-box; font-family: arial; font-size: 14px; font-weight: 700; text-align: start;"><a href="https://www.polarismarketresearch.com/industry-analysis/cancer-tumor-profiling-market/request-for-sample">Request a Sample Copy </a></span></td></tr></tbody></table><p style="text-align: justify;">Globally there is a rise in cancer patients every year. According to the WHO this disease is considered to be the second leading cause mortalities in the year 2019. It is also estimated that that 1 out of 6 deaths were due to cancer. WHO has marked that one third of deaths from this disease are due to 5 leading behavioral and dietary risks. The factors include high body mass index, low fruit and vegetable intake, lack of physical activity, tobacco use, and alcohol use. Tobacco is one of the leading factors for the rise in the prevalence of cancer and mortalities that approximately 22%. According to WHO, in 2015, there were around 17.6 million cases related to cancer that increases to 18.1 million cases in 2018 and nearly 9.6 million mortalities. The rising number of patients is the major factor for the growth of global cancer/tumor profiling market.</p><p style="text-align: justify;">Certified techniques have been identified that can reduce the time taken to identify tumors and stages of advancement along with improved support for cancer research. Moreover, major investments by major biotechnology companies for the development of new therapies and new techniques of drug design are being witnessed across countries. This has significantly driven market growth and is expected to sustain growth during the forecast period. Biomarkers play a significant part in the design of a drug regime for cancer patients by quickly developing gene profiling techniques and individualizing targeted therapies. Currently, genome based prognostic biomarkers can be used to prognosticate multiple kinds of cancer in the clinical phases. Researchers, however, contend that conversion difficulties are hindering the broad divide between the phase of biomarker discovery and their clinical conversion. The acquisition of tumor genomic data is seen as the most significant step in cancer prediction, diagnosis, and therapy.</p><p style="text-align: justify;">Next Generation Sequencing (NGS) is a sophisticated technique for the sequence that can be used for accurate tumor DNA genomic sequencing. The interpreted data contribute much more quickly to the assessment of tumor purity and the magnitude of disease progression. The primary benefit of NGS is the complete exotic sequence which helps examine all protein-coding areas of the human genome. It also enables whole genome sequencing to be useful for analysis of protein coding and non-coding areas in the human genome. Such advances in technology are one of the primary drivers of global cancer/tumor profiling market.</p><p style="text-align: justify;">Moreover, the growing demand for personalized medicine further provides substantial opportunities for the tumor profiling market. The personalized medicine is defined as typical care in the treatment that is customized as per an individual patient. There have been several types of research going on presently to develop personal medicine based on the patients. Several factors should be considered before providing personal medicine to a patient. Firstly, the doctors have to detect the type or the symptoms of cancer that can be developed in a patient. Detection is important for the surgeon or the doctor, to find the best suited therapy that can treat the person. For developing a personalized medicine tumor profiling need to be taken into account as these tests will eventually reveal the various conditions of the patients such as detection of the individual developing a specific type of disease.</p><p style="text-align: left;"><b>Read More: <a href="https://www.polarismarketresearch.com/industry-analysis/cancer-tumor-profiling-market">https://www.polarismarketresearch.com/industry-analysis/cancer-tumor-profiling-market</a></b></p>Mr. Rohit Chavanhttp://www.blogger.com/profile/08706042746893719666noreply@blogger.com0tag:blogger.com,1999:blog-8782964280890501499.post-12361971539109270322020-11-05T06:11:00.003-08:002020-11-05T06:11:38.171-08:00Active Pharmaceutical Ingredient Market Size is Estimated to Reach $306.1 Billion By 2027 | PMR<p style="text-align: justify;"><b> New York City, 5 Nov 2020: </b>The global <a href="https://www.polarismarketresearch.com/industry-analysis/active-pharmaceutical-ingredients-market"><b>active pharmaceutical ingredient (API) market</b></a> size is expected to reach USD 306.1 billion by 2027 according to a new study by Polaris Market Research. The report “<b><i>Active pharmaceutical Ingredient (API) market Share, Size, Trends, Industry Analysis Report, By Product Type (Monoclonal Antibodies, Immunoglobulin, Cytokines, Insulin, Peptide Hormones, Blood Factors, Peptide Antibiotics, Vaccines, Small Molecule Antibiotics, Highly Potent Active Pharmaceutical Ingredient (HPAPI), and Others); By Form (Aqueous, Non-Aqueous Liquid, and Dry Powder); By Manufacturer Type (Captive, and Merchant); By Application (Cardiology, Oncology, CNS & Neurology, Orthopedic, Endocrinology, Pulmonology, Gastroenterology, Nephrology, Ophthalmology, and Others), By Regions; Segment Forecast, 2020 –2027</i></b>”gives a detailed insight into current market dynamics and provides analysis on future market growth.</p><table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto;"><tbody><tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhOE5AGXnhCGA2UEhwyFm20G9ZqAmaFUSoBzSXW4dJKRTYiXxHoxn3qdeDTRa-Qz-X3Uiul8TGGAG_1fM_mO_VBaHh_QBK0S-mTKlRyYCt3E4QWzvzBT46dbPk6fRAZSWonoMaQZQQFmZ8/s694/Active-Pharmaceutical-Ingredient-Market.png" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" data-original-height="302" data-original-width="694" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhOE5AGXnhCGA2UEhwyFm20G9ZqAmaFUSoBzSXW4dJKRTYiXxHoxn3qdeDTRa-Qz-X3Uiul8TGGAG_1fM_mO_VBaHh_QBK0S-mTKlRyYCt3E4QWzvzBT46dbPk6fRAZSWonoMaQZQQFmZ8/s320/Active-Pharmaceutical-Ingredient-Market.png" width="320" /></a></td></tr><tr><td class="tr-caption" style="text-align: center;"><a href="https://www.polarismarketresearch.com/industry-analysis/active-pharmaceutical-ingredients-market/request-for-sample" rel="noopener" style="background-color: white; box-sizing: border-box; color: rgb(0, 117, 231) !important; display: inline-block; font-family: Roboto, sans-serif; font-size: 15px; padding: 5px 0px; text-decoration-line: none !important;" target="_blank"><em style="box-sizing: border-box;"><span style="box-sizing: border-box; font-weight: 700;">request for sample pages</span></em></a></td></tr></tbody></table><p style="text-align: justify;">Active Pharmaceutical Ingredient (API) is a substance involved in the finished pharmaceutical product (FPP), aimed to enhance the pharmacological activity or have direct impact in the cure, mitigation, diagnosis, treatment of disease or in modifying, correcting or restoring physiological functions in the human body. Drug products are composed of various components, API is the primary ingredient of a drug product, for instance, capsule or a tablet. APIs form used in the formulation is the most stable crystalline form, thermo-dynamically. </p><p style="text-align: justify;">The prominent factors favoring the global market include the sudden outbreak of novel corona virus, which is rapidly escalating the demand for pharmaceuticals and thereby fueling the overall market growth. Additionally, rise in aging population, rising cases of cardiovascular diseases, cancer, AIDs, other infectious diseases, are further contributing to augmenting demand for APIs that are used in drugs. For instance, according to a report published in March 2020, by World Health Organization (WHO), the number of COVID-19 patients increased to 200,000 and in almost after twelve-day period, the number would exceed by 100,000. Moreover, rising incidence of cardiovascular, oncology, diabetes and lifestyle diseases coupled with rising geriatric populace is furthermore surging the overall demand for the global market.</p><p style="text-align: justify;"><b>Market participants such as</b> AbbVie Inc., Albemarle Corporation, AstraZeneca, Aurobindo Pharma, Boehringer Ingelheim, Bristol-Myers Squibb, Cipla Inc., Dr. Reddy’s Laboratories Ltd., ELI Lilly and Company, F. Hoffmann-La Roche, GlaxoSmithKline PLC, Lonza Group, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer, Inc., Sanofi, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd. are some of the key players operating in the global market.</p><p style="text-align: justify;">Players in the market are focusing on developing active pharmaceutical Ingredient to suffice the rising demand of critical drugs for the treatment of numerous diseases. For the treatment of various diseases such as cancer, HIV, arthritis, Hepatitis-B, diabetes, cardiovascular diseases, Aids and various others, which are responsible for the majority of deaths across the globe, the innovation and demand for pharmaceuticals has witnessed elevated graph over the few decades. This has further resulted in rise in growth of API during the past years and also over the forecast period.</p><p style="text-align: justify;">Major players in the market are strengthening their capabilities to enhance their product portfolio and further establish their market place. For instance, on July, 2020, Advert International signed an agreement for the acquisition of RA Chem Pharma Ltd, an integrated pharmaceutical company by Micro Labs Ltd. for USD 1.7 billion. Advert International aims for building one of the major API platforms and is expected to leverage their operational and financial resources across the globe to scale RA Chem Pharma.</p><p style="text-align: justify;"><b style="text-align: left;">Browse more information on "Active Pharmaceutical Ingredient (API) Market" <a href="https://www.polarismarketresearch.com/industry-analysis/active-pharmaceutical-ingredients-market">https://www.polarismarketresearch.com/industry-analysis/active-pharmaceutical-ingredients-market</a></b></p>Mr. Rohit Chavanhttp://www.blogger.com/profile/08706042746893719666noreply@blogger.com0tag:blogger.com,1999:blog-8782964280890501499.post-43483459045608472092020-11-05T06:05:00.001-08:002020-11-05T06:05:03.580-08:00Anti-Aging Market Size is Estimated to Reach USD 29.8 billion by 2027 | Polaris Market Research<p style="text-align: justify;"><b>New York City, 5 Nov 2020:</b> The global <a href="https://www.polarismarketresearch.com/industry-analysis/anti-aging-market"><b>anti-aging market </b></a>size is expected to reach USD 29.8 billion by 2027 according to a new study by Polaris Market Research. Aging is associated with decline in bodily functions or changes in the human body. It is also associated with steady loss of strength, muscle mass and power, in combination with reduction in lung capacity and maximal rate of oxygen consumption. Beauty and skin health is considered one of the prominent factors that represents overall perception of health and well-being in consumers. Anti-aging products and treatments help combat the consumer skin by masking, preventing and reducing signs of aging.</p><p style="text-align: justify;">The prominent factors favoring the market growth include rise in aging population, globally. As per the statistics published by the United Nations, through its World Population Prospects working group, in 2019, by 2050, there would be 1 in 6 old age people (over 65 years), as compared to 1 in 11 in 2019. These old age group accounts for one fifth of the total population in 17 countries, and it is projected to be increased by the end of this century in 155 countries, covering 61 per cent of the global population. This is mainly due to increase in life expectancy and declining fertility rates among the people.</p><table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto;"><tbody><tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEikXhvpGGnMw_UyNgBJmc2LiWrDTlNGIKt5MKxPtxUDLWZ-tCemHAm8TEZdSJP_cr4sPwl0qCuQ2m_hLeAfPgpubQrp_eC2aYnXDpIzLYHDrdAkhOrJRvl4BYNHe1NHc66AxmrV285YxF8/s694/Anti-Aging-Market.png" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" data-original-height="302" data-original-width="694" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEikXhvpGGnMw_UyNgBJmc2LiWrDTlNGIKt5MKxPtxUDLWZ-tCemHAm8TEZdSJP_cr4sPwl0qCuQ2m_hLeAfPgpubQrp_eC2aYnXDpIzLYHDrdAkhOrJRvl4BYNHe1NHc66AxmrV285YxF8/s320/Anti-Aging-Market.png" width="320" /></a></td></tr><tr><td class="tr-caption" style="text-align: center;"><a href="https://www.polarismarketresearch.com/industry-analysis/anti-aging-market/request-for-sample" rel="noopener" style="background-color: white; box-sizing: border-box; color: rgb(0, 117, 231) !important; display: inline-block; font-family: Roboto, sans-serif; font-size: 15px; padding: 5px 0px; text-decoration-line: none !important;" target="_blank"><em style="box-sizing: border-box;"><span style="box-sizing: border-box; font-weight: 700;">request for sample pages</span></em></a></td></tr></tbody></table><p style="text-align: justify;">In 2019, there were around 703 million aged over 65+. Eastern and South East Asia accounted for the largest share of around 260 million, followed by Europe and North America with over 200 million. It is projected that in South Asia the biggest increase in old age would be seen in South Korea, Taiwan, and Singapore.</p><p style="text-align: justify;">Signs of aged skin becomes gradually noticeable and is associated with loss of elasticity, loss of volume, appearance of wrinkles and fine lines. Rising consciousness among the populace regarding younger looking skin is furthermore surging the overall demand for anti-aging products and treatments, and thereby enhances the market growth.</p><p style="text-align: justify;"><b>Market participants such as</b> Estée Lauder Companies Inc., Allergan plc, Avon Products Inc., L’Oreal SA, Procter & Gamble Co., Unilever, Shiseido Company, Limited, Beiersdorf AG, CCA Industries Inc., Christian Dior SA, Johnson & Johnson, Chanel SA, Neutrogena Corporation, Oriflame Cosmetics, La Prairie Group AG, Clarins, Ella Bache, NeoStrata Company Inc., Unity Biotechnology, Inc., Beauty Counter, Lumenis Ltd. and Revlon Inc., are some of the key players operating in the global market.</p><p style="text-align: justify;">Players in the market are focusing on developing anti-aging products and treatments to meet the rising demand of consumers to fight aging. In line with this, in January, 2020, Pure Nutrition Ltd, launched a range of cosmetic products in India, to tap the country’s booming beauty market. The range consisted one hair care and three skin care products produced from natural and organic ingredients and having anti-aging, anti-pollution and anti-fatigue properties.</p><p style="text-align: justify;">Additionally, in September 2019, MONAT corp., specializing in natural anti-aging hair care products introduced MONAT skincare products. The launched facilitated eight skincare products designed to tackle anti-aging issues of the consumers with being cruelty-free, naturally based and vegan.</p><p style="text-align: justify;"><b>Read More: <a href="https://www.polarismarketresearch.com/industry-analysis/anti-aging-market">https://www.polarismarketresearch.com/industry-analysis/anti-aging-market</a></b></p>Mr. Rohit Chavanhttp://www.blogger.com/profile/08706042746893719666noreply@blogger.com0tag:blogger.com,1999:blog-8782964280890501499.post-63396108500283512072020-11-05T05:57:00.008-08:002020-11-05T05:57:55.853-08:00Coronary Stent Market Worth $15.28 Billion By 2027 | CAGR: 7.7% | PMR<p style="text-align: justify;"><b> New York City, 5 Nov 2020: </b>The global<a href="https://www.polarismarketresearch.com/industry-analysis/coronary-stent-market"> <b>coronary stent market </b></a>size is expected to reach USD 15.28 billion by 2027 according to a new study by Polaris Market Research. The global Coronary Stent Market offers prominent opportunities for the players to flourish in the untapped low-income countries, particularly in the Asia Pacific region. Market is characterized by intense competition, flooded with many local players that develop safe, cost-effective, easy to use, and widely available products. These players adopt innovative strategies and develop full proof devices to provide product differentiation.</p><p style="text-align: justify;">Cath labs or cardiac catheterization laboratories in hospitals and ambulance conduct both diagnostic and therapeutic procedures. For example, The Frankel Cardiovascular Center, has 4 cardiac catheterization laboratory that are used for coronary procedures, these labs complement two hybrid operating rooms. These medical facilities use technologically advanced such as DES, BMS and Bioresorbable Vascular Scaffold stents to improve the quality of life, offer better patient healthcare benefits like efficacy and safety profile, and minimize hospital stays. These procedures are not complex and are mostly performed in ASCs and digital cath labs. For Example, Absorb GT1 has clinically proven that the artery is able to dilate and contract, called vasomotion that is similar to healthy blood vessels.</p><table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto;"><tbody><tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj-_bQuaHsUrhnembEsYNQdIHqv_nytg5anfNRiL5N3Ca-tRuFtLAp7SwDxBJDCwN5-Z7KBXMmHYse0THdwBg9cQrWC2V7TEi48_SozMBd8b5Qto_5yp7BkUcBLAwI6kaZItXot1gOPtcY/s725/Coronary-Stents-Market-size.png" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" data-original-height="302" data-original-width="725" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj-_bQuaHsUrhnembEsYNQdIHqv_nytg5anfNRiL5N3Ca-tRuFtLAp7SwDxBJDCwN5-Z7KBXMmHYse0THdwBg9cQrWC2V7TEi48_SozMBd8b5Qto_5yp7BkUcBLAwI6kaZItXot1gOPtcY/s320/Coronary-Stents-Market-size.png" width="320" /></a></td></tr><tr><td class="tr-caption" style="text-align: center;"><a href="https://www.polarismarketresearch.com/industry-analysis/coronary-stent-market/request-for-sample" rel="noopener" style="background-color: white; box-sizing: border-box; color: rgb(0, 117, 231) !important; display: inline-block; font-family: Roboto, sans-serif; font-size: 15px; padding: 5px 0px; text-decoration-line: none !important;" target="_blank"><em style="box-sizing: border-box;"><span style="box-sizing: border-box; font-weight: 700;">request for sample pages</span></em></a></td></tr></tbody></table><p style="text-align: justify;">The incidence of CVDs is on the rise in globally. This is due to the lifestyle changes such as smoking and alcohol over consumption, un-healthy food habits, and lack of physical inactivity. These factors cause obesity, heart related ailments and diabetes that can lead to CVDs. In 2015, according to Global prevalence of Diabetes, India is seeing increasing diabetic patients which accounts for more than 62 million diabetic patients.</p><p style="text-align: justify;">To treat this growing cases of CVDs, players are using advanced technologies to develop innovative products such as Bioresorbable Vascular Scaffold and nano-coated stents. Improvement in healthcare infrastructure has allowed medical facilities to adopt these advanced systems for disease treatment in spite of its cost. This will lead many people to undergo stent procedure to treat cardiac disorders. Public awareness of this procedure and associated systems and benefits will further lead many people to undergo them.</p><p style="text-align: justify;"><b>Market participants such as </b>Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, Biotronik, Terumo Corporation, Shandong JW Medical Systems, Cook Medicals, Biosensors International Group (acquired by Blue Sail Medical Co., Ltd), Stentys SA, B. Braun Melsungen AG, Liaoning Biomedical Materials, Meril Life Sciences, MicroPort Scientific Corporation, Lepu Medicals, Vascular Concepts, and Translumina GmbH are some of the key players operating in the concerned market.</p><p style="text-align: justify;">For instance, in July, 2020, Blue Sail Medical Co., Ltd established its new Blue Sail Shanghai Innovation Center (BSIC), which was built after months of rigorous effort and well equipped with GMP facilities. The company entered into cardio-vascular area after acquiring Biosensors International Group. BSIC’s focus would be co-operating with the research and development based in Germany and Singapore to develop innovative coronary intervention products including stent from scratch.</p><p style="text-align: left;"><b>Read More : <a href="https://www.polarismarketresearch.com/industry-analysis/coronary-stent-market/request-for-sample">https://www.polarismarketresearch.com/industry-analysis/coronary-stent-market/request-for-sample</a></b></p><p style="text-align: justify;"><br /></p><div style="text-align: justify;"><br /></div>Mr. Rohit Chavanhttp://www.blogger.com/profile/08706042746893719666noreply@blogger.com0tag:blogger.com,1999:blog-8782964280890501499.post-23071450965650610922020-11-02T06:32:00.003-08:002020-11-02T06:53:11.530-08:00Legal Marijuana Market Worth $90.5 Billion By 2027 | CAGR: 21.2% | Polaris Market Research<p style="text-align: left;"><b style="text-align: justify;">New York City, 2 Nov 2020:</b><span style="text-align: justify;">
The global </span><b style="text-align: justify;"><a href="https://www.polarismarketresearch.com/industry-analysis/legal-marijuana-market/speak-to-analyst">Legal
Marijuana Market</a></b><span style="text-align: justify;"> size is expected to be more than USD 90.5 billion by
2027 according to a new study by Polaris Market Research. Increasing
penetration of Legal Marijuana in applications other than recreational such as
pharmaceuticals, and increasing medical prospects are some of the factors
propelling the market growth. Legal Marijuana is being used for treating a wide
variety of diseases including cancer, arthritis, neurological conditions,
Parkinson’s diseases, among others and this factor is expected to propel market
growth.</span></p><p class="MsoNormal" style="text-align: justify;"><o:p></o:p></p>
<p class="MsoNormal" style="text-align: justify;">Pain management therapies segment
is witnessing rapid growth across the globe. This therapy is increasingly being
used to treat elders suffering from chronic pain. Legal Marijuana are finding
wide applications in pain management therapies due to their overall efficacy,
easy availability and relatively low prices as compared to other counterparts
and this trend is expected to benefit the overall Legalized Cannabis market
growth over the forecast period.</p><table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto;"><tbody><tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgwtkcn0km0mRZ8k5ydXwZBgSjiV00dBW6fLeX0B8jnTL1yHdzeJTrZrhyphenhyphenbNElsi8iaIFqc_OEeFl9QfqelPnf-MYr7QycO7eg6qJtfyIJLuPiD59uv-glNV-Yi7AodBtPW0ffM7aPGptw/s579/Legal+Marijuana+Market.png" style="margin-left: auto; margin-right: auto;"><img border="0" data-original-height="264" data-original-width="579" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgwtkcn0km0mRZ8k5ydXwZBgSjiV00dBW6fLeX0B8jnTL1yHdzeJTrZrhyphenhyphenbNElsi8iaIFqc_OEeFl9QfqelPnf-MYr7QycO7eg6qJtfyIJLuPiD59uv-glNV-Yi7AodBtPW0ffM7aPGptw/s320/Legal+Marijuana+Market.png" width="320" /></a></td></tr><tr><td class="tr-caption" style="text-align: center;"><a href="https://www.polarismarketresearch.com/industry-analysis/legal-marijuana-market/request-for-sample" rel="noopener" style="background-color: white; box-sizing: border-box; color: #0075e7; display: inline-block; font-family: Roboto, sans-serif; font-size: 15px; padding: 5px 0px; text-decoration-line: none;" target="_blank"><em style="box-sizing: border-box;"><span style="box-sizing: border-box; font-weight: 700;">request for sample pages</span></em></a></td></tr></tbody></table><p class="MsoNormal" style="text-align: justify;">Several studies have pointed out
that the usage of Legal Marijuana to treat mental disorders yield desired and
positive results. Changes in lifestyle and fast paced lifestyles, advent of
nuclear families, social media, among others are some of the factors that have
resulted in rising number of mental disorders such as depression, anxiety
disorders, Alzheimer’s diseases, etc. This trend is expected to benefit the
demand for Legal Marijuana for mental disorder treatment and thus boosting the
market growth.</p><p class="MsoNormal" style="text-align: justify;"><o:p></o:p></p>
<p class="MsoNormal" style="text-align: justify;">North America emerged as the
largest market for Legal Marijuana in the year 2019, and the segment is
expected to continue to lead the market in terms of penetration and is also
expected to witness a robust growth rate during the forecast period. A major contributor
to this scenario is the strong demand from the U.S. There is widespread usage
of Legal Marijuana in the country and this has resulted in the U.S. being one
of the foremost consumers of Legal Marijuana across the globe.</p><p class="MsoNormal" style="text-align: justify;"><o:p></o:p></p>
<p class="MsoNormal" style="text-align: justify;">Many states in the U.S. have
issued clear directives as well as regulations pertaining to the usage of Legal
Marijuana. This has resulted in widespread generalization pertaining to its
usage. Other states which have not yet drafted such regulations, are under
constant pressure from advocate groups, associations, among others for doing
the same. All in all, the advent of Legal Marijuana is set to have a long-term
impact on the food & beverage industry in the country.</p><p class="MsoNormal" style="text-align: justify;"><o:p></o:p></p>
<p class="MsoNormal" style="text-align: justify;"><b>Some of the major market
participants include</b> Cannabis Sativa, Inc., United Cannabis Corporation.,
Tikun Olam, Ltd., Tilray., Lexaria Corp., GW Pharmaceuticals, plc., Canopy
Growth Corporation., Aurora Cannabis, Aphria, Inc, and Maricann Group, Inc.
among others. Broadening of product portfolio, strong analysis of consumer
buying behavior, and efforts taken to increase awareness regarding Legal
Marijuana usage are some of the key industry scenarios. Companies often have to
navigate through different regulations in different parts of the world and have
ensure strict compliance to it prior launching their products. In countries
such as the U.S., different regulations exist for different states.</p><p class="MsoNormal" style="text-align: justify;"><o:p></o:p></p>
<p class="MsoNormal" style="text-align: justify;"><b style="text-align: left;">Read More : <a href="https://www.polarismarketresearch.com/industry-analysis/legal-marijuana-market/request-for-sample">https://www.polarismarketresearch.com/industry-analysis/legal-marijuana-market/request-for-sample</a></b></p>
<p class="MsoNormal"><b><o:p> </o:p></b></p>Mr. Rohit Chavanhttp://www.blogger.com/profile/08706042746893719666noreply@blogger.com0tag:blogger.com,1999:blog-8782964280890501499.post-49807853479031686792020-11-02T06:22:00.004-08:002020-11-02T06:22:48.966-08:00Peptide Based Cancer Therapeutics Market Worth $17.18 Billion By 2027 | CAGR: 9.1% | PMR<p><b style="text-align: justify;">New York City, 2 Nov 2020:</b><span style="text-align: justify;"> The global </span><b style="text-align: justify;"><a href="https://www.polarismarketresearch.com/industry-analysis/peptide-based-cancer-therapeutics-market/request-for-sample">peptide-based
cancer therapeutics market</a></b><span style="text-align: justify;"> size is expected to reach USD 17.18 billion
by 2027 according to a new study by Polaris Market Research. Peptides are
compounds that are created by natural or artificial biological linking of amino
acid monomers. Peptides are being widely used in therapeutics to treat several
ailments, including cancer owing to their precision based nature, targeting
solid tumor cells in the body. Peptide based cancer therapeutics have shown
effective results against cancer as opposed to conventional cancer treatments,
without much side effects.</span></p><p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><o:p></o:p></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;">Peptide based therapies in the treatment of cancer are majorly
classified as pure play peptide therapy, vaccines based on peptide, and peptide
conjugate nanomaterials. These therapies possess several advantages over others
such as easy administration, specificity in targeting tumor tissues, fewer side
effects as compared to drugs, and low cost of peptides.</p><p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><br /></p><table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto;"><tbody><tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjDtNXn6fJZM-lY9nsNK7gmbqVkf5LGLzCezjj70jeHJ-_j3GoWVT_-Lt40yCxEStIomh5lB-yrmABFvQYJprk14aWUqBmrAyPiQZl4uw-KGPSOhxYvUPAMMx_1J0PbjfusRv5Z23k1OmY/s733/Peptide-Based-Cancer-Therapeutics-Market.png" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" data-original-height="302" data-original-width="733" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjDtNXn6fJZM-lY9nsNK7gmbqVkf5LGLzCezjj70jeHJ-_j3GoWVT_-Lt40yCxEStIomh5lB-yrmABFvQYJprk14aWUqBmrAyPiQZl4uw-KGPSOhxYvUPAMMx_1J0PbjfusRv5Z23k1OmY/s320/Peptide-Based-Cancer-Therapeutics-Market.png" width="320" /></a></td></tr><tr><td class="tr-caption" style="text-align: center;"><a href="https://www.polarismarketresearch.com/industry-analysis/peptide-based-cancer-therapeutics-market/request-for-sample" rel="noopener" style="background-color: white; box-sizing: border-box; color: rgb(0, 117, 231) !important; display: inline-block; font-family: Roboto, sans-serif; font-size: 15px; padding: 5px 0px; text-decoration-line: none !important;" target="_blank"><em style="box-sizing: border-box;"><span style="box-sizing: border-box; font-weight: 700;">request for sample pages</span></em></a></td></tr></tbody></table><p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;">The factors propelling the market growth are the increasing prevalence
of cancer across the world, cancer screening programs in emerging countries,
and the high specificity of peptide based cancer vaccines. In 2016, according
to analysis by NCA (National Cancer Center), 1,010,200 cancer cases were
recorded, with 576,100 male patients and 434,100 women cases. The mortality
rate in 2016 recorded a high with more than 374,000 cancer deaths in the
country, particularly deaths associated with the most common colorectal cancer
followed by gastric, lung, prostrate and breast cancers.</p><p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><o:p></o:p></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><b><i>Market participants such as</i></b> AstraZeneca PLC, Abbott,
Allergan plc, Teva Pharmaceuticals, Pfizer Inc., Takeda Pharmaceutical, Amgen,
Inc., Johnson & Johnson, AbbVie Inc., and Valeant Pharmaceuticals Inc., are
some of the key players operating in the concerned market. In January 2020,
Sony Brook University (SBU) extended its funding on FABP5 inhibitors to 2025 by
demonstrating novel approach to treat last stage prostate cancer. According to
the researchers of the SBU specific fatty acid binding protein (FABP) may be
help in stopping cancer.</p><p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><o:p></o:p></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;">In June 2017, AstraZeneca along with National Cancer Institute Eleven
entered into cooperative research and development agreement with Eleven
Biotherapeutics to develop Vicinium in combination with AstraZeneca’s immune
checkpoint inhibitor, Imfinzi to treat non-muscle invasive bladder cancer.</p><p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><o:p></o:p></p>
<p class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: left;"><b>Read More : <a href="https://www.polarismarketresearch.com/industry-analysis/peptide-based-cancer-therapeutics-market">https://www.polarismarketresearch.com/industry-analysis/peptide-based-cancer-therapeutics-market</a></b></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><o:p> </o:p></p>Mr. Rohit Chavanhttp://www.blogger.com/profile/08706042746893719666noreply@blogger.com0tag:blogger.com,1999:blog-8782964280890501499.post-22225799045678675012020-11-02T06:18:00.006-08:002020-11-02T06:18:42.295-08:00Percutaneous Coronary Intervention (PCI) Devices Market Worth $11.4 Billion By 2027 | CAGR: 7.1% <p><b style="text-align: justify;">New York City, 2 Nov 2020:</b><span style="text-align: justify;"> The global</span><b style="text-align: justify;"> <a href="https://www.polarismarketresearch.com/industry-analysis/percutaneous-coronary-intervention-pci-devices-market">percutaneous
coronary intervention (PCI) devices market</a></b><span style="text-align: justify;"> size is expected to reach
USD 11.4 billion by 2027 according to a new study by Polaris Market Research.
Coronary artery disease (CAD) is causing most of deaths globally. The factors
contributing to the disease include sedentary lifestyle, smoking, obesity,
hereditary factors and alcohol usage. The mortality rate of CAD has been
tremendously increasing grabbing the attention for researchers and clinicians
globally, With the technological advancements in stent technologies, design of
the guide wires, advent of next generation</span><span style="text-align: justify;">
</span><span style="text-align: justify;">coronary catheters (percutaneous transluminal coronary angioplasty
(PTCA), percutaneous transluminal angioplasty (PTA) balloon catheters ), and
the availability of coronary guide wires (steel based, nitinol based )
increased the treatment scope of the coronary heart diseases.</span></p><p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><o:p></o:p></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;">The emergence of dedicated catheterization labs in high income
countries is also pivotal factor influencing the growth of the PCI devices
market. The next generation Cath labs offers advanced services and performs
interventional therapeutic procedures such as PCI, PTCA, epicardial ablations
of ventricular tachycardia, aortic valve replacements and mitral valve repairs.
Additionally, they also perform interventional cardiac electrophysiological
procedures, pacemaker implantation and cardiac defibrillator implantation. The
number of PCI procedures and other cardiac interventions is substantially
increasing with the increase in the cardiovascular diseases globally.</p><p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><br /></p><table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto;"><tbody><tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh3tLxITZ0XvGAaowWtJjw95R0ZKgMOkgUcg95hf4K0DTCpocr8Ef4oscH4-XRgNG2nbcbogVuyMJYp4Lph3-EKc26yqhtTcBct2_SO95f8sbNntB1l1ZGnSI5v_wObq3G8ykbhLEXOkl8/s694/Perecutaneous-Coronary-Intervention-Devices-Market.png" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" data-original-height="302" data-original-width="694" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh3tLxITZ0XvGAaowWtJjw95R0ZKgMOkgUcg95hf4K0DTCpocr8Ef4oscH4-XRgNG2nbcbogVuyMJYp4Lph3-EKc26yqhtTcBct2_SO95f8sbNntB1l1ZGnSI5v_wObq3G8ykbhLEXOkl8/s320/Perecutaneous-Coronary-Intervention-Devices-Market.png" width="320" /></a></td></tr><tr><td class="tr-caption" style="text-align: center;"><em style="background-color: white; box-sizing: border-box; color: rgb(0, 117, 231) !important; display: inline-block; font-family: Roboto, sans-serif; font-size: 15px; padding: 5px 0px; text-decoration-line: none !important;"><span style="box-sizing: border-box; font-weight: 700;">R<a href="https://www.polarismarketresearch.com/industry-analysis/percutaneous-coronary-intervention-pci-devices-market/request-for-sample" rel="noopener" style="background-color: white; box-sizing: border-box; color: rgb(0, 117, 231) !important; display: inline-block; font-family: Roboto, sans-serif; font-size: 15px; padding: 5px 0px; text-decoration-line: none !important;" target="_blank">equest for sample pages</a></span></em></td></tr></tbody></table><p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;">To increase the performance of multi-specialty hospitals, many
government and private hospitals are setting up catheterization labs for
improved service offerings. This concept is gaining popularity for PCI
procedures in Canada, the US, the UK, Germany, and other western countries. The
factors favoring its growth include the conversion of physician’s office to
alternate hospital providers, surgeons’ relationship with the manufacturers to
eliminate the need of general practitioner officers (GPO), and the expansion of
services provided by the hospitals.</p><p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><o:p></o:p></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><o:p> </o:p></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><b>Market participants such as</b> Abbott, B. Braun, ASAHI INTECC
Company Limited, Biosensors International Group, Ltd, Boston Scientific
Corporation, C. R. Bard, BIOTRONIK, Comed BV, Cook, Meril Lifesciences, Cordis,
Medtronic PLC, Merit Medical System, and Terumo Corporation are some of the key
players operating in the percutaneous coronary intervention (PCI) devices
market. Key vendors are investing huge amounts into their R&D and
introducing new technologies and launching new products to stay competitive in
this market. Several products were launched in the recent past with the latest
next generation technology which caters the growing needs of the physician and
the patients.<o:p></o:p></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in;"><b><o:p> </o:p></b></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in;"><b>Read More
: <a href="https://www.polarismarketresearch.com/industry-analysis/percutaneous-coronary-intervention-pci-devices-market">https://www.polarismarketresearch.com/industry-analysis/percutaneous-coronary-intervention-pci-devices-market</a><o:p></o:p></b></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><o:p> </o:p></p>Mr. Rohit Chavanhttp://www.blogger.com/profile/08706042746893719666noreply@blogger.com0tag:blogger.com,1999:blog-8782964280890501499.post-77043559652981797502020-11-02T06:13:00.004-08:002020-11-02T06:13:46.552-08:00Dialysis Catheters Market Worth $976.2 Million By 2027 | CAGR: 4.8% | Polaris Market Research<p><b style="text-align: justify;"><span style="font-family: Georgia, serif; font-size: 10pt; line-height: 107%;">New
York City, 2 Nov 2020:</span></b><span style="font-family: Georgia, serif; font-size: 10pt; line-height: 107%; text-align: justify;"> The global <b><a href="https://www.polarismarketresearch.com/industry-analysis/dialysis-catheters-market">dialysis
catheters market</a> </b>size is expected to reach USD 976.2 million by 2027
according to a new study by Polaris Market Research Dialysis catheters is
basically used for exchange of blood to and from a dialysis machine and the
patient under treatment. Catheters has two lumens viz. venous and arterial.
Arterial lumen carries blood away from the heart and supplies to dialysis
machine whereas venous lumen returns blood back to the heart from the machine.
Flow rates are maintained at in between 200 to 500 ml/min. The common site for
placing catheters is superior vena cava (SVC), by puncturing jugular vein
present in the neck, towards chest. SVC can also be inserted through
sub-clavian vein. The market is driven by few notable factors such as life
style changes resulting in kidney disorders, rising population of old people
seeking more medical care, and surge in independent dialysis care centers in
the U.S. and Europe. According to statistics published by Lancet, in 2017, 1.2
million people across the globe died from CKD. The global mortality rate from
CKD stood at 41.5% from 2014 to 2017. Moreover, in 2017, total recorded cases
of CKDs were 697.5 million at a prevalence rate of 9.1%.</span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><span style="font-family: Georgia, serif; font-size: 10pt;">Dialysis
centers offer exclusive dialysis services for the treatment of various renal
disorders. There are more than 16,800 dialysis centers that offer services in
more than 161 countries. DaVita is one of the leading dialysis service
providers with more than 2,500 dialysis centers globally, while Fresenius
Medical Care has more than 2,200 dialysis centers.</span></p><p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto;"><tbody><tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgy8YkVQzgz1GsIARzOTFezB3yLah5r9Kw_oQAJEJrnMPU2ajG7VODGj5NExk1ARe_p1f8WdXs9SSznrOy8A7zWQ3tcWKQPLDhhgnI1KaC3Zao6PyxGkpVrs5yrT8S6myCFKviqf0caXzA/s694/Dialysis-Catheters-Market-Size.png" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" data-original-height="303" data-original-width="694" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgy8YkVQzgz1GsIARzOTFezB3yLah5r9Kw_oQAJEJrnMPU2ajG7VODGj5NExk1ARe_p1f8WdXs9SSznrOy8A7zWQ3tcWKQPLDhhgnI1KaC3Zao6PyxGkpVrs5yrT8S6myCFKviqf0caXzA/s320/Dialysis-Catheters-Market-Size.png" width="320" /></a></td></tr><tr><td class="tr-caption" style="text-align: center;"><em style="background-color: white; box-sizing: border-box; color: rgb(0, 117, 231) !important; display: inline-block; font-family: Roboto, sans-serif; font-size: 15px; padding: 5px 0px; text-decoration-line: none !important;"><span style="box-sizing: border-box; font-weight: 700;">R<a href="https://www.polarismarketresearch.com/industry-analysis/dialysis-catheters-market/request-for-sample" rel="noopener" style="background-color: white; box-sizing: border-box; color: rgb(0, 117, 231) !important; display: inline-block; font-family: Roboto, sans-serif; font-size: 15px; padding: 5px 0px; text-decoration-line: none !important;" target="_blank">equest for sample pages</a></span></em></td></tr></tbody></table><span style="font-family: Georgia, serif; font-size: 10pt;"><br /></span><span style="font-family: Georgia, serif; font-size: 10pt;">Home
based renal care has become a norm in the U.S., in line with this in April
2020, the U.S. based renal care provider, Outset Medical, announced that it
received FDA approval for its home based Tablo hemodialysis system. The system
is all in one dialysis care machine handling both dialysate production and
water purification. Similarly, in February 2020, U.S. based startup CloudCath
raised funding of USD 12 million for commercializing its device for home
monitoring of dialysis.</span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><b><span style="font-family: Georgia, serif; font-size: 10pt; line-height: 107%;">Market
participants such</span></b><span style="font-family: Georgia, serif; font-size: 10pt; line-height: 107%;"> as Fresenius Medical Care, NIPRO Medical
Corporation, DaVita, Medical Components Inc., NIKKISO CO., LTD, B. Braun,
Foshan Special Medical, Toray Medical, Jiangxi Sanxin Medtec, AngioDynamics
Inc., Asahi Kasei Medical Co., Ltd., Baxter International, NxStage Medical,
Inc., Shenzhen Shunmei Medical Technology., Outset Medical, Inc. and ALLMED
MEDICAL CORP. are some of the key players operating in the concerned market.
Companies are introducing innovative catheters technology to reduce
complications. In February 2020, Bluegrass Vascular Technologies received FDA
approval for its new inside out catheters access system. This system would be
boon for those who have obstructed veins.</span></p>
<p class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: left;"><span style="color: black; font-family: "Georgia",serif; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-GB;"><o:p> </o:p></span><b style="text-align: left;"><span style="font-family: Georgia, serif; font-size: 10pt; line-height: 107%;">Read
More : <a href="https://www.polarismarketresearch.com/industry-analysis/dialysis-catheters-market">https://www.polarismarketresearch.com/industry-analysis/dialysis-catheters-market</a></span></b></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><o:p> </o:p></p>Mr. Rohit Chavanhttp://www.blogger.com/profile/08706042746893719666noreply@blogger.com0tag:blogger.com,1999:blog-8782964280890501499.post-26927063575750729812020-11-02T06:10:00.001-08:002020-11-02T06:10:07.428-08:00U.S. Durable Medical Equipment Market Worth $76.32 Billion By 2026 | CAGR: 6.3% | PMR<p><b style="text-align: justify;"><span style="font-family: Georgia, serif; font-size: 10pt;">New
York City, 2 Nov 2020:</span></b><span style="font-family: Georgia, serif; font-size: 10pt; text-align: justify;">
The U.S. Durable Medical Equipment
market size is expected to reach USD 76.32 billion by 2026 according to a new
study by Polaris Market Research. The medical device manufacturers are
developing new and improved equipment based on durability and reliability to
improve the quality of life of the patients in need. With growing demand for
home healthcare, the adoption of home care equipment is also increasing.
Several new organizations are established that are launching and scaling
advanced home care models to move primary, acute, and palliative care to the
home. There are numerous dynamics that are driving patient’s preference for
healthcare settings specifically towards home which in-turn is enhancing the
adoption of durable medical equipment across various regions.</span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><span style="font-family: Georgia, serif; font-size: 10pt;">The
primary factor driving the growth of durable medical equipment market in the
U.S. is growing aging population and increasing demand for assisted care in a
comfortable environment. Currently, there are over 40 million people in the
U.S. alone aged 65 years & above and this number is anticipated to double
by 2050. Rapidly growing geriatric population, which forms the key target
population for DME, is anticipated to bolster the growth of the market over the
forecast period. Furthermore, increasing prevalence of chronic diseases,
growing technological advancements, and increasing government initiatives to
improve healthcare are some other factors fueling the growth of this market.
The rising geriatric population is expected to increase susceptibility toward
chronic conditions such as diabetes, cardiovascular disorders, and other
lifestyle disorders. With an ever-increasing prevalence of diseases and baby
boomer population, healthcare expenditure levels are expected to continue to
grow during the forecast period.</span></p><p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto;"><tbody><tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgjGHUpApipA_H9c9aMuw8948WPDNwYLSpzbYHbBuxAOsXyq1D7IdeCVuHlclm7HvtjHE5mXNf2OcUvrHuqj2j2eQrqYEDRDJrgQug0MK8TMwJT0uJxHpCrcbEE4wOI0bsvGYHFazDjGt8/s701/US-Durable-Medical-Equipment-Market-2020.png" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" data-original-height="307" data-original-width="701" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgjGHUpApipA_H9c9aMuw8948WPDNwYLSpzbYHbBuxAOsXyq1D7IdeCVuHlclm7HvtjHE5mXNf2OcUvrHuqj2j2eQrqYEDRDJrgQug0MK8TMwJT0uJxHpCrcbEE4wOI0bsvGYHFazDjGt8/s320/US-Durable-Medical-Equipment-Market-2020.png" width="320" /></a></td></tr><tr><td class="tr-caption" style="text-align: center;"><a href="https://www.polarismarketresearch.com/industry-analysis/us-durable-medical-equipment-market/request-for-sample" rel="noopener" style="background-color: white; box-sizing: border-box; color: rgb(0, 117, 231) !important; display: inline-block; font-family: Roboto, sans-serif; font-size: 15px; padding: 5px 0px; text-decoration-line: none !important;" target="_blank"><em style="box-sizing: border-box;"><span style="box-sizing: border-box; font-weight: 700;">request for sample pages</span></em></a><br /></td></tr></tbody></table><span style="font-family: Georgia, serif; font-size: 10pt;">The growth of home healthcare as a cost-effective
alternative over hospital stay is expected to serve this market as a key driver
over the forecast period. Though many factors are driving the market growth,
there are several issues that have a negative impact on the market. Failure to
meet the desired performance is another vital reason why healthcare
professionals hesitate from using DME, especially personal mobility devices. At
times, while carrying obese patients, these equipment tend to break, which
usually happens due to wear and tear. In such situations, the patient is at
greater risk and prone to severe accidents and injuries. Also, DME are
primarily used in the home healthcare settings and the fact that remuneration
for home health & personal aides are significantly lower than other personal
care & service workers and well below the median for all occupations
discourages individuals to take up home health aide as a profession, which is
expected to restrain market growth.</span><span style="font-family: Georgia, serif; font-size: 10pt;"> </span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><span style="font-family: Georgia, serif; font-size: 10pt;">The
U.S. DME market is expected to witness a significant growth during the forecast
period. Based on several government initiatives and insurance coverage, it is
easy for the patients to use these equipment at a low cost. Both Medicare and
Medicaid offer coverage for DME that are prescribed by the doctor for home use.
Most DME can be purchased without prescription, however, some devices such as
oxygen equipment require prescription. In addition, prescription becomes
essential in case of reimbursement or the coverage.</span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><span style="font-family: Georgia, serif; font-size: 10pt;">Furthermore,
numerous companies are launching technologically advanced systems to improve
the usage and sales of DME. For instance, in August 2018 Somnoware, launched
its enhanced durable medical equipment DME ordering capability for enterprise
healthcare systems. Also, in May 2019 Breg, Inc., launched Breg Vision 7.0, in
Apple’s app store, the next generation of its paperless workflow management
system for orthopedic providers, to automates and optimizes in-house durable
medical equipment (DME) programs. Such activities not only improves the
existing technologies but also helps smoothen the purchase and usage process
for the patients.</span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><b><span style="font-family: Georgia, serif; font-size: 10pt;">The key
players in the market include</span></b><span style="font-family: Georgia, serif; font-size: 10pt;"> Invacare Corporation, Sunrise Medical,
ArjoHuntleigh, Hill Rom, Inc, Stryker Corporation, Medline Industries Inc.,
Drive Medical, GF Health Products Inc., and Carex Health Brands, Inc. among
others.</span></p><p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><b style="text-align: left;"><span style="font-family: "Georgia",serif; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Read More : <a href="https://www.polarismarketresearch.com/industry-analysis/us-durable-medical-equipment-market">https://www.polarismarketresearch.com/industry-analysis/us-durable-medical-equipment-market</a></span></b></p>Mr. Rohit Chavanhttp://www.blogger.com/profile/08706042746893719666noreply@blogger.com0tag:blogger.com,1999:blog-8782964280890501499.post-82572248253510756812020-11-02T06:06:00.004-08:002020-11-02T06:06:37.262-08:00Prefilled Syringes Market Worth $10.1 Billion By 2027 | CAGR: 9.8% | Polaris Market Research<p style="text-align: justify;"><b><span style="font-family: Georgia, serif; font-size: 10pt;">New
York City, 2 Nov 2020:</span></b><span style="font-family: Georgia, serif; font-size: 10pt;">
The global<b> <a href="https://www.polarismarketresearch.com/industry-analysis/prefilled-syringes-market">pre-filled
syringes market</a></b> size is expected to reach USD 10.1 billion by 2027
according to a new study by Polaris Market Research. The pharmaceutical
industry is witnessing a rapid rise in bio-pharmaceuticals which is increasing
demand for various advanced drug delivery devices, including prefilled
syringes. Currently, more than 60% of the drugs in the clinical trials are
biologics which needs to be administered parenterally.</span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><span style="font-family: Georgia, serif; font-size: 10pt;">Prefilled
syringes (PFS) are efficient, reliable and convenient method for parenteral
drug administration. These help the pharmaceutical companies to minimize drug
waste and increase product life span which in turn leads to cost savings. PFS
reduces the product wastage by preventing the dose overfill by four to five
percent. This is especially advantageous for biological drugs as their
manufacturing and product costs are too high and have low bulk manufacturing
capacity. The product costs of some biologicals are as high as USD 2,000 per
dose. PFS lowers the overall cost-per-dosage-unit compared to conventional
syringe and vials. Hence, the demand for PFS is rising strongly in all customer
segments; pharmaceutical companies, physicians and patients.</span></p><p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto;"><tbody><tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj_eMELyDy7LDRQivz-oiARHlELcWQz_XC3H_bP0q-Ut3UtJ-RiF_HRGfsOCM12xhot0PIJPJMBH7iQz2Cx-3uDiHE-uqF0KVRca8vOAs-ZDEM5X3NXKSM2vt0px3tJMD2pOvwa573-_Og/s695/Prefilled-Syringes-Market.png" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" data-original-height="302" data-original-width="695" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj_eMELyDy7LDRQivz-oiARHlELcWQz_XC3H_bP0q-Ut3UtJ-RiF_HRGfsOCM12xhot0PIJPJMBH7iQz2Cx-3uDiHE-uqF0KVRca8vOAs-ZDEM5X3NXKSM2vt0px3tJMD2pOvwa573-_Og/s320/Prefilled-Syringes-Market.png" width="320" /></a></td></tr><tr><td class="tr-caption" style="text-align: center;"><span style="background-color: white; font-family: Roboto, sans-serif; font-size: 15px;"><b>Know more about this report: </b></span><a href="https://www.polarismarketresearch.com/industry-analysis/prefilled-syringes-market/request-for-sample" rel="noopener" style="background-color: white; box-sizing: border-box; color: rgb(0, 117, 231) !important; display: inline-block; font-family: Roboto, sans-serif; font-size: 15px; padding: 5px 0px; text-decoration-line: none !important;" target="_blank"><em style="box-sizing: border-box;"><span style="box-sizing: border-box; font-weight: 700;">request for sample pages</span></em></a></td></tr></tbody></table></p><p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><span style="font-family: Georgia, serif; font-size: 10pt;">It is
estimated that nearly 50% of the diabetics live in China, India, US, Brazil and
Indonesia. There is immense scope for PFS market penetration in these emerging
countries due to huge patient base. Many patients are choosing to
self-administer drugs in non-medical settings to reduce their healthcare and
other related treatment costs. Administering a PFS involves lesser steps and
lesser dexterity in comparison to the conventional needle and syringe.</span><span style="font-family: Georgia, serif; font-size: 10pt;"> </span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><span style="color: black; font-family: "Georgia",serif; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-GB;"><o:p> </o:p></span><span style="font-family: Georgia, serif; font-size: 10pt;">PFS is
convenient to use in non-medical settings as it is ergonomic, provide the
accurate dose and preserves the sterility of the drug for over 6 months. PFS
are increasingly being used for self-administration by users with chronic
diseases such as diabetes and rheumatoid arthritis.</span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><span style="color: black; font-family: "Georgia",serif; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-GB;"><o:p><b> </b></o:p></span><span style="font-family: Georgia, serif; font-size: 10pt;"><b>Market
participants such as</b> Becton Dickinson (BD), Medpro, Haselmeier AG, Stevanato
Group, Owen Mumford, SCHOTT, Unilife Corporation, OMPI, Fresenius Kabi,
Catalent, Vetter Pharma International GmbH, Gerresheimer, Weigao Corporation,
West Pharmaceutical Services, Inc., and Nipro Medical Corporation are some of
the key players operating in the concerned market.</span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify;"><span style="font-family: Georgia, serif; font-size: 10pt;">With
surge in COVID-19 cases, the U.S. government is liable to increase domestic
medical facility to cope up with the future scenario. In line with this, in May
2020, the Department of Defense (DOD) and the U.S. Department of Health and
Human Services awarded a contract of worth USD 138 million to the U.S. based
ApiJect Systems America to start Project Jumpstart. The project would revamp
the country’s production capability, by October 2020, to be independent in
manufacturing more than 100 million prefilled syringes, using blow-fill-seal
aseptic plastic manufacturing technology.Read More: </span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: 0.0001pt; text-align: left;"><b><span style="font-family: "Georgia",serif; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Read More : <a href="https://www.polarismarketresearch.com/industry-analysis/prefilled-syringes-market">https://www.polarismarketresearch.com/industry-analysis/prefilled-syringes-market</a></span></b></p>
<p class="MsoNormal" style="text-align: justify;"><span style="font-family: "Georgia",serif; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><o:p> </o:p></span></p>Mr. Rohit Chavanhttp://www.blogger.com/profile/08706042746893719666noreply@blogger.com0tag:blogger.com,1999:blog-8782964280890501499.post-12765587340614288672020-11-02T05:56:00.003-08:002020-11-02T05:56:18.125-08:00Platelet Aggregation Devices Market Worth $1,556.8 Million By 2027 | CAGR: 20.1% | PMR<p></p><p class="MsoNormal" style="line-height: normal; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;"></p><p class="MsoNormal" style="line-height: normal; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;"><b><span style="color: black; font-family: "Georgia",serif; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-GB;">New
York City, 2 Nov 2020:</span></b><span style="color: black; font-family: "Georgia",serif; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-GB;"> The
global <b>platelet aggregation devices market</b> size is expected to
reach USD 1,556.8 million by 2027 according to a new study by Polaris Market
Research. Platelet aggregation is the biological process where the platelet
cells are employed in a process to prevent bleeding through vaso-constriction
for rapid clot formation. The whole process is mediated via platelet aggregating
factor (PAF). The quantitative and qualitative defects of platelets lead to
increased bleeding. The high reactivity of platelets in the patients having
anti-platelet therapy results in thromboembolic complications.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; mso-margin-top-alt: auto; text-align: justify;"><span style="color: black; font-family: "Georgia",serif; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-GB;">Platelet function related disorders can be either
inherited or acquired. The inherited platelet function disorders include Von
Willebrand disease, Glanzmann’s thrombasthenia, Bernard-Soulier syndrome,
Storage pool disease. The acquired platelet dysfunction may be caused by
chronic conditions such as kidney failure (uremia), Myelodysplastic syndrome
(MDS), Leukemias (chronic myeloid leukemia or CML; acute myeloid leukemia or
AML).<o:p></o:p></span></p><p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; mso-margin-top-alt: auto; text-align: justify;"><table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto;"><tbody><tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhIOMFv8S9PCwSLDdFbqgXkIPs4BDVmXHLNquG2OtL3GIKUIawb6cWHLgQBR_mtN7brFPpXRl6f3uRNTsVdsjgypDpbdrC8-dHcp0JSISSjOLs-AOj6JlLz_o5BgO8APpMGd8vTx0O9TOg/s694/Platelet-Aggregation-Devices-Market.png" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" data-original-height="302" data-original-width="694" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhIOMFv8S9PCwSLDdFbqgXkIPs4BDVmXHLNquG2OtL3GIKUIawb6cWHLgQBR_mtN7brFPpXRl6f3uRNTsVdsjgypDpbdrC8-dHcp0JSISSjOLs-AOj6JlLz_o5BgO8APpMGd8vTx0O9TOg/s320/Platelet-Aggregation-Devices-Market.png" width="320" /></a></td></tr><tr><td class="tr-caption" style="text-align: center;"><span style="background-color: white; font-family: Roboto, sans-serif; font-size: 15px;">Know more about this report: </span><a href="https://www.polarismarketresearch.com/industry-analysis/platelet-aggregation-devices-market/request-for-sample" rel="noopener" style="background-color: white; box-sizing: border-box; color: rgb(0, 117, 231) !important; display: inline-block; font-family: Roboto, sans-serif; font-size: 15px; padding: 5px 0px; text-decoration-line: none !important;" target="_blank"><em style="box-sizing: border-box;"><span style="box-sizing: border-box; font-weight: 700;">request for sample pages</span></em></a><br /></td></tr></tbody></table><span style="font-family: Georgia, serif; font-size: 10pt;"><br /></span></p><p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; mso-margin-top-alt: auto; text-align: justify;"><span style="font-family: Georgia, serif; font-size: 10pt;">Some acquired platelet disorders are temporary
because of the decreased function of platelets due to anti-platelet
medications, non-steroidal anti-inflammatory drugs (NSAIDs), tricyclic
antidepressants, antihistamines and some antibiotics. The platelet function
testing is transitioned from diagnostics for heritable diseases to a functional
one for platelet functional therapies. The rapid usage of anti-platelet
therapy, mainly dual anti-platelet therapy has changed the focus of platelet
function testing from diagnostics to therapeutics. The market is driven by few
notable factors such as the recent surge in infectious diseases (COVID-19)
requiring rapid serological tests, innovations in platelet aggregation
mechanisms, systems and consumables, and worldwide rise in chronic ailments.
Specialized tests based on platelet aggregation include light transmission
platelet aggregometry on platelet-rich plasma (LTA), impedance whole blood
aggregometry (WBA), Lumi-aggregometry and flow cytometry.</span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; mso-margin-top-alt: auto; text-align: justify;"><span style="color: black; font-family: "Georgia",serif; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-GB;">Automated haematology analyzers can be used to
obtain platelet counts over a wide range of values using optical counting
methods like light scatter or fluorescence. Screening tests such as prothrombin
time (PT) or activated partial thromboplastin time (aPTT) are more standardized
and fully automated.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; mso-margin-top-alt: auto; text-align: justify;"><span style="color: black; font-family: "Georgia",serif; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-GB;">Number of reagents are available in the market to
carry out the platelet function tests. These reagents include collagen,
thrombin, ADP, vasopressin, epinephrine and ristocetin. Collagen, ADP were used
in routine platelet aggregation studies for the evaluation of qualitative
platelet function disorders.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; mso-margin-top-alt: auto; text-align: justify;"><b><span style="color: black; font-family: "Georgia",serif; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-GB;">Market participants such as</span></b><span style="color: black; font-family: "Georgia",serif; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-GB;"> F. Hoffmann La-Roche Ltd.,
Drucker Diagnostics, Haemonetics Corporation, Sysmex Corporation, Siemens
Healthineers, Chrono-log Corporation, Instrumentation Laboratory, Accriva
Diagnostics, Matis Medical, Helena Laboratories Corporation, Sienco, Inc.,
Bio/Data Corporation, Tem Group, WerfenLife, S.A., Laboratory Corporation of
America Holdings, Sentinel CH. S.p.A., and Aggredyne, Inc. are some of the key
players operating in the concerned market.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; mso-margin-top-alt: auto;"><b><span style="color: black; font-family: "Georgia",serif; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-GB;">Read
More: <span style="color: blue;"><a href="https://www.polarismarketresearch.com/industry-analysis/platelet-aggregation-devices-market/request-for-sample">https://www.polarismarketresearch.com/industry-analysis/platelet-aggregation-devices-market/request-for-sample</a></span></span></b></p><p></p><p></p>Mr. Rohit Chavanhttp://www.blogger.com/profile/08706042746893719666noreply@blogger.com0tag:blogger.com,1999:blog-8782964280890501499.post-44411357335321910822020-11-02T05:50:00.004-08:002020-11-02T05:50:39.230-08:00IV Tubing Sets and Accessories Market Future Technological Trends and Business Opportunities By 2027<p class="MsoNormal" style="text-align: justify;"><b>New York City, 2 Nov 2020:</b> The
global <b><a href="https://www.polarismarketresearch.com/industry-analysis/iv-tubing-sets-accessories-market/request-for-discount-pricing">IV
tubing sets and accessories market</a></b> size is expected to reach USD
1,153.6 million by 2027 according to a new study by Polaris Market Research. IV
tubing sets and accessories basically include different parts namely, infusion
line, piercing needle, flow regulator, and luer connector attached with IV tube
and the needle. These set are often known as intravenous therapy, designed to
administer hydrating fluid, drug, medication directly into the circulatory
system. Infusion supplies should be sterile disposable single time use
products.<o:p></o:p></p>
<p class="MsoNormal" style="text-align: justify;">Most of the insulin pumps require
infusion set to administer insulin into diabetic patients. Flexible tube
connects pump reservoir, moving insulin from pump to needle beneath your skin.
The selection of the infusion set often decided on the basis of pump
compatibility with other accessories, needle insertion angle, gauge and length
of cannula, and tube size.</p><table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto;"><tbody><tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgNUoTn999xpyao5HbUpx8cb6fVyuSN86lSTyZqubLBkEgpWumrKggT_hHyjdXKSx4L_eV69tmXVJIzP9qpNkwbc_oDmAkL1uyeyakF6Oe_m_pu17ptBnk1xcuS_FSdfm5LpUDuI1dYbNI/s225/IV+Tubing+Sets+and+Accessories.jpg" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" data-original-height="225" data-original-width="225" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgNUoTn999xpyao5HbUpx8cb6fVyuSN86lSTyZqubLBkEgpWumrKggT_hHyjdXKSx4L_eV69tmXVJIzP9qpNkwbc_oDmAkL1uyeyakF6Oe_m_pu17ptBnk1xcuS_FSdfm5LpUDuI1dYbNI/s0/IV+Tubing+Sets+and+Accessories.jpg" /></a></td></tr><tr><td class="tr-caption" style="text-align: center;"><a href="https://www.polarismarketresearch.com/industry-analysis/iv-tubing-sets-accessories/request-for-sample" rel="noopener" style="background-color: white; box-sizing: border-box; color: rgb(0, 117, 231) !important; display: inline-block; font-family: Roboto, sans-serif; font-size: 15px; padding: 5px 0px; text-decoration-line: none !important;" target="_blank"><em style="box-sizing: border-box;"><span style="box-sizing: border-box; font-weight: 700;">request for sample pages</span></em></a></td></tr></tbody></table><p class="MsoNormal" style="text-align: justify;">European market saw a large set of
these apparatus procured through group purchasing organizations in volumes at
the reduced prices. In China, the market is expected to surpass Europe owing to
dramatic entry of 800 million new people through its nationwide universal
insurance system.</p><p class="MsoNormal" style="text-align: justify;"><o:p></o:p></p>
<p class="MsoNormal" style="text-align: justify;">The global market is driven by a rise
in chronic ailments such as cardiac disorders and diabetes, a sudden surge in
infectious diseases, an increasing proportion of geriatrics using home-based
infusion therapies<b><i>. According to the International Diabetes Federation
(IDF), the number of people suffering from diabetes were 415 million in 2015,
which is expected to reach approximately 640 million by 2040.</i></b><o:p></o:p></p>
<p class="MsoNormal" style="text-align: justify;"><b>Market participants such as</b> Baxter
International Inc., Becton, Dickinson and Company (CareFusion), Perfect Medical
Ind. Co., Ltd, Hospira Inc. (Pfizer Inc.), B. Braun Melsungen AG, Smiths
Medical, Fresenius Kabi, C.R. Bard, Inc., Zyno Medical, ICU Medical Inc., Nipro
Corporation, Vygon, Poly Medicure, Health Line International Corporation, and
Dynarex Corporation are some of the key players operating in the concerned
market.<o:p></o:p></p>
<p class="MsoNormal" style="text-align: justify;">New and existing players are focusing
on product innovation and new launches inclined towards dedicated therapy. The
U.S. based medical start-up DiaTech Diabetic Technologies announced to launch
SmartFusion technology based infusion set, which alerts diabetics with errors
on real time basis. This has thumb sized fluid pressure sensing device for
insulin pumps to monitor errors in the insulin delivery and sends signals to
physicians through Bluetooth connection. According to the company’s claim
globally, more than 120 million infusion sets are sold and it is estimated that
around 60 per cent insulin pumps experience set failures, resulting in loss of
USD 426 million of annual wastage from un-viable sites.<o:p></o:p></p>
<p class="MsoNormal" style="text-align: justify;"><b>Read More: <a href="https://www.polarismarketresearch.com/industry-analysis/iv-tubing-sets-accessories-market">https://www.polarismarketresearch.com/industry-analysis/iv-tubing-sets-accessories-market</a><o:p></o:p></b></p>
<p><b style="text-align: justify;"> </b> </p>Mr. Rohit Chavanhttp://www.blogger.com/profile/08706042746893719666noreply@blogger.com0tag:blogger.com,1999:blog-8782964280890501499.post-20317675438190143912020-07-20T08:09:00.006-07:002020-07-20T08:09:47.877-07:00Needle-Free IV Connectors Market Size To Surpass $1,647.7 Million By 2027 | CAGR: 10.2% | PMR<div dir="ltr" style="text-align: left;" trbidi="on">
<div style="text-align: justify;">
<b>New York City, 20 Jul 2020: </b>The global <b>needle-free IV connectors market </b>size is expected to reach <b>USD 1,647.7 million by 2027 </b>according to a new study by Polaris Market Research. Needle free IV connectors (NFC) are small needleless devices used within intra-venous (IV) catheters, administration sets, and syringes. NFC is the basic medical supply present in any healthcare facility to administer fluid, drug or medication in different vascular access systems. These needle-free systems are designed with the purpose to reduce needle stick injuries, bacterial contamination in the blood to improve patient outcome.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The complications associated with the needle based connectors such as catheter based blood stream infections and the catheter lumen occlusion are acting as the drivers for the NFC market. The set of NFCs are coming up with superior designs and features to reduce the length of hospital stays and economic burden.</div>
<div style="text-align: justify;">
<br /></div>
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><img alt="Needle-free IV Connector Market" height="174" src="https://www.polarismarketresearch.com/wp-content/uploads/2020/07/Needle-Free-IV-Connectors-Market-Size.png" style="margin-left: auto; margin-right: auto;" width="400" /></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><b><a href="https://www.polarismarketresearch.com/industry-analysis/needle-free-iv-connectors-market/request-for-sample" target="_blank">Request for sample pages</a></b> </td></tr>
</tbody></table>
<div style="text-align: justify;">
The prominent factors responsible for the growth of NFCs market the rising hospital admission rate, particularly among geriatrics, needle stick injuries among healthcare workers, and superior quality as compared to conventional systems. In 2016, the Center of Disease Control and Prevention (CDC) estimated more than 8.5 million people in the U.S have peripheral artery disease (PAD), out of which approximately 20% of the individuals were above age 60 years. The prevalence of the PAD is estimated equal among the men and women population. The primary reason behind the widespread of these diseases is less awareness among the population, especially in growing economies of the APAC region.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Market participants such </b>as RyMed Technologies, LLC, Baxter International Inc., CareFusion Corporation, B. Braun Melsungen AG, Nexus Medical LLC, Becton, Dickinson and Company, ICU Medical, Inc., and Vygon S.A. are some of the key players operating in the concerned market. The factors such as superior designs, unique features, user friendliness with the healthcare workers, price, technology, and strong distribution in the geographical area are the competitive forces impacting the player presence in the area. The bigger companies are focusing on signing long term exclusive distribution agreement to remain dominant force in the market. In May 2019, B. Braun and Nexus Medical signed an agreement to distribute TKO-6P luer activated anti-reflux device. This will increase customer coverage with enhanced patient care for both the parties.</div>
<div style="text-align: left;">
<b><br /></b></div>
<div style="text-align: left;">
<b>Read More: <a href="https://www.polarismarketresearch.com/industry-analysis/needle-free-iv-connectors-market">https://www.polarismarketresearch.com/industry-analysis/needle-free-iv-connectors-market</a></b></div>
<div style="text-align: justify;">
<br /></div>
</div>
Mr. Rohit Chavanhttp://www.blogger.com/profile/08706042746893719666noreply@blogger.com0tag:blogger.com,1999:blog-8782964280890501499.post-86294531305892071102020-07-20T08:06:00.004-07:002020-07-20T08:06:46.125-07:00Human Microbiome Therapeutics Market Size To Surpass $1,544.6 Million By 2027 | PMR<div dir="ltr" style="text-align: left;" trbidi="on">
<div style="text-align: justify;">
<b>New York City, 20 Jul 2020: T</b>he global <b>human microbiome therapeutics market size is expected to reach USD 1,544.6 million by 2027</b> according to a new study by Polaris Market Research. Microbiome refers to the residing micro-organisms genomes in the human body, particularly in the gut. The human body comprises more than 100 trillion microbes and around 2 million microbe genomes. These microbiota plays a significant role in the body’s physiological functions and includes viruses, bacteria, and fungi. Primarily it has Bacteroidetes (gram negative) and Firmicutes, commonly Clostridium and Lactobacillus sp. (gram positive). The majority of these are strict anaerobes, with fungi and archaebacteria comprising less than 1 per cent of the total population.</div>
<div style="text-align: justify;">
<br /></div>
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><img alt="Human Microbiome Therapeutics Market" height="174" src="https://www.polarismarketresearch.com/wp-content/uploads/2020/07/Human-Microbiome-Therapeutics-Market-Size.png" style="margin-left: auto; margin-right: auto;" width="400" /></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><b><a href="https://www.polarismarketresearch.com/industry-analysis/human-microbiome-therapeutics-market/request-for-sample" target="_blank">Request for sample pages </a></b></td></tr>
</tbody></table>
<div style="text-align: justify;">
The global market is driven by an increased focus on microbiome based early diagnosis of diseases, increase in the prevalence of diseases due to dysbiosis, rising collaborations, and strongly funded government backed microbiome research projects. In November 2019, the Million Microbiome of Humans Project (MMHP) was launched in collaboration with France, Denmark, China, Latvia, Sweden and other countries to co-operate in meta-genomic research. The aim is to create the largest human microbiome database from analyzing more than one million samples gathered from reproductive tract, gut, skin, and other organs in the next few years.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Market participants such as</b> Enterome Bioscience, Biotagenics, Seres Therapeutics, Oxidien Pharmaceuticals, LLC, BoobyBiome, 4D Pharma PLC, UBiome, Carbiotix, E.I. du Pont de Nemours and Company, Finch Therapeutics, GNUbiotics Sciences, ClearB Therapeutics, GoodBelly, GoodGut, Synlogic, Second Genome, 16S Technologies, 5QBD-Biotech, Vedanta Biosciences, Holobiome, Commense, Ferring Pharmaceuticals, Evelo Biosciences, CoreBiome, Igen Biolab Group, ViThera Pharmaceuticals, DermBiont, Hyggut, Embion Technologies, Lactobio, BiomX, Exeliom Biosciences, and LNC Therapeutics are some of the key players operating in the concerned market.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Recently, in July 2020, 4D pharma plc., the UK based pharma company engaged in the development of live bio-therapeutics announced that patient enrollment for its phase II trial of its candidate oral immune-modulator MRx-4DP0004 for patients hospitalized with COVID-19 is open, and dosing to start very soon. The company is world leader in the production of live bio-therapeutics (live microbiome used to cure disease). Its products are the orally delivered single strain bacteria, which are naturally present in the human gut.</div>
<div style="text-align: left;">
<b><br /></b></div>
<div style="text-align: left;">
<b>Read More : <a href="https://www.polarismarketresearch.com/industry-analysis/human-microbiome-therapeutics-market">https://www.polarismarketresearch.com/industry-analysis/human-microbiome-therapeutics-market</a></b></div>
<div style="text-align: justify;">
<br /></div>
</div>
Mr. Rohit Chavanhttp://www.blogger.com/profile/08706042746893719666noreply@blogger.com0tag:blogger.com,1999:blog-8782964280890501499.post-60309780412592896912020-07-20T08:03:00.002-07:002020-07-20T08:03:45.413-07:00Wearable Medical Devices Market Size To Surpass $85.6 Billion By 2027 | CAGR: 24.8% | Polaris Market Research<div dir="ltr" style="text-align: left;" trbidi="on">
<div style="text-align: justify;">
<b>New York City, 20 Jul 2020:</b> The global <b>Wearable Medical Devices market size is expected to reach USD 85.6 billion by 2027 </b>according to a new study by Polaris Market Research.Wearable medical devices are defined as the autonomous devices worn by the individual to provide medical or fitness monitoring and support over a period of time. They are either worn as a body accessory or being embedded in cloth or shoes. They incorporate non-invasive sensors, wireless transmission, real time data processing capabilities, and also provide medical feedback.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Recent developments in wearable medical devices include alert mechanisms, decision support systems, and real time analysis. These wearables offer point of care, and remote management for rehabilitating individuals, disabled and chronically ill.</div>
<div style="text-align: justify;">
<br /></div>
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><img alt="Wearable Medical Device market" height="159" src="https://www.polarismarketresearch.com/wp-content/uploads/2020/07/Wearable-Medical-Devices-Market-Size.png" style="margin-left: auto; margin-right: auto;" width="400" /></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><b><a href="https://www.polarismarketresearch.com/industry-analysis/wearable-medical-devices-market/request-for-sample" target="_blank">Request for sample pages </a></b></td></tr>
</tbody></table>
<div style="text-align: justify;">
The prominent factors favoring the wearable medical devices market growth include an increase in the prevalence of lifestyle-related diseases, consumer awareness towards fitness, and advancement in technology and medical innovation with ever increasing interest of consumer electronic companies. According to the study published by the International Diabetes Federation (IDF), in 2015, there were approximately 415 million diabetic people and it is expected to increase to 640 million by 2040. The high prevalence of diabetes is an important driver boosting market growth.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
With a spike in infectious diseases over the past decade, the Stanford Healthcare Innovation Lab (SHIL) set up a team to study the impact of wearables to track infectious diseases. Moreover, in April 2020, Scripps Research Translational Institute (SRTI) launched DETECT, under which data from activity trackers and smart watches would be integrated into public health surveillance program for proactive disease tracking and population health programs.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Market participants such as</b> Medtronic plc, OMRON Corp., Biotelemetry Inc., Apple, Inc., Koninklijke Philips, Dexcom Inc., Abbott Laboratories, Verily Life Sciences, GE Healthcare, Bio-Beat Technologies, Masimo Corporation, iRhythm Technologies, Inc., Preventice Solutions, Inc., CONTEC Medical Systems Co. Ltd, VitalConnect, Minttihealth, Biotricity Inc., Cyrcadia Asia Limited., Garmin Ltd, Xiaomi Technologies, ten3T healthcare, Fitbit, Inc., and Huawei Corporation are some of the key players operating in the Wearable Medical Devices market.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Players in the market are focusing on developing low cost wearable accessible to all strata of the population within the geographic footprint. In line with this, India based Muse Wearables is manufacturing a wrist based wearable tracker at a cost of INR 3,500. With this, it will continuously monitor skin temperature, blood O2 saturation levels, and heart rate to track body vital signs to diagnose COVID-19 symptoms in early stages. The device is Bluetooth enabled and could be connected via ‘<b>Muse Health App</b>’.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: left;">
<b>Read More : <a href="https://www.polarismarketresearch.com/industry-analysis/wearable-medical-devices-market">https://www.polarismarketresearch.com/industry-analysis/wearable-medical-devices-market</a></b></div>
</div>
Mr. Rohit Chavanhttp://www.blogger.com/profile/08706042746893719666noreply@blogger.com0tag:blogger.com,1999:blog-8782964280890501499.post-40291137487456442112020-07-20T07:59:00.000-07:002020-07-20T07:59:47.237-07:00CT Scanner Market Size To Surpass $8.40 Billion By 2027 | CAGR: 6.4% | Polaris Market Research<div dir="ltr" style="text-align: left;" trbidi="on">
<div style="text-align: justify;">
<b>New York City, 20 Jul 2020:</b> The global <b>CT Scanner market size is expected to reach USD 8.40 billion by 2027</b> according to a new study by Polaris Market Research.Computed tomography is an imaging devices which enables users to look inside the specimen without cutting it. It utilizes computer systems and rotating X-rays machines to produce cross sectional images. In medical, it offers images of blood vessels, bones, and soft tissues to find any ailments or bone fractures in the human body. CT scanning is non-invasive, fast, accurate, and painless procedure. In emergency situation, it provides details of internal injuries and hemorrhage, which saves many human lives.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The prominent factors favoring the market growth include improvement in the Scanner technology, miniaturization resulting in portable CT Scanner, and rising prevalence in bone-related disorders coupled with road traffic accidents. According to the statistics published by the U.S. Center for Disease and Control (CDC), around 30 million people take part in sports related activities in the U.S. alone. Of this, individuals aged 15 to 20 accounted for around 2 million injuries and more than 30,000 hospital admissions per year.<br />
<br />
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><img alt="CT Scanner market" height="172" src="https://www.polarismarketresearch.com/wp-content/uploads/2020/06/CT-Scanners-Market-Size.png" style="margin-left: auto; margin-right: auto;" width="400" /></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><b><a href="https://www.polarismarketresearch.com/industry-analysis/ct-scanner-market/request-for-sample" target="_blank">Request for sample pages </a></b></td></tr>
</tbody></table>
</div>
<div style="text-align: justify;">
Moreover, many start-ups are employing <a href="https://www.polarismarketresearch.com/industry-analysis/artificial-intelligence-market" target="_blank"><b>artificial intelligence (AI)</b></a> for an accurate diagnosis. According to the study published in NVIDIA, AI could significantly drop error rate in cancer diagnosis by more than 85 per cent. In line with this, Aidoc, an Israel based start up is employing AI to decipher medical scans and in 2016, the U.S. based AI medical imaging platform Behold.ai, came up with its proprietary “red dot algorithm”. This algorithm has 90 per cent accuracy and faster scanning capability.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Market participants such as </b>CurveBeam, Hitachi Medical Corporation, Neusoft, Samsung, Canon Medical Systems, GE Healthcare, Medtronic Inc., Accuray, Koning Corporation, Xoran, Koninklijke Philips, Carestream, Planmed Oy, Siemens Healthineers, Shenzhen Anke High-Tech, and United Imaging Technologies are some of the key players operating in the concerned market.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The players in the market are competing on different parameters such as strategic partnerships and agreements, exclusive service offerings, after-sales service, providing financing options, and warranties. In cost-sensitive untapped markets, the players are penetrating through government contracts, leasing and exclusive collaborations.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Read More : <a href="https://www.polarismarketresearch.com/industry-analysis/ct-scanner-market">https://www.polarismarketresearch.com/industry-analysis/ct-scanner-market</a></b></div>
</div>
Mr. Rohit Chavanhttp://www.blogger.com/profile/08706042746893719666noreply@blogger.com0tag:blogger.com,1999:blog-8782964280890501499.post-85360430049526902292020-07-20T07:56:00.002-07:002020-07-20T07:56:34.323-07:00Vaccine Adjuvants Market Size Worth $1,305.7 Million By 2027 | Polaris Market Research<div dir="ltr" style="text-align: left;" trbidi="on">
<div style="text-align: justify;">
<b>New York City, 20 Jul 2020:</b> The global <b>Vaccine Adjuvants Market </b>size is expected to reach <b>USD 1,305.7 million by 2027</b> according to a new study by Polaris Market Research. Adjuvant is defined as a substance which in combination with vaccine invigorates antigen specific immune reactions to increase specificity and immunogenicity of marketed vaccines administered in any individual. Adjuvants augment the impact of a vaccine providing increased immunity towards any particular infectious disease. It triggers positive immune response by mimicking pathogen associated molecular pattern (PAMP), which include lipo-polysaccharide, liposomes, cell walls of bacteria, and endo-cytosed and un-methylated nucleic acids. Adjuvant imparts beneficial effects to vaccines in several ways such as increasing its potency to grasp the higher degree of immunogenicity, reducing the number of repeated vaccinations, antigen dose reduction, widening antibody responses of the individual, and inducing T-cell responses.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The global market is driven by the recent surge in infectious diseases, extensive research on vaccines, and funding from the government. European Union (EU) through EU programme Horizon 2020, has formed ENOVA, a network on vaccine adjuvants. This will bring both industry experts and stakeholders working in the areas of vaccine research and development and adjuvant research to reduce side effects and efficacy of new developing vaccines.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Market participants such as</b> GlaxoSmithKline Plc, Novavax, Inc., Statens Serum Institut, Viscogel AB, VaxLiant LLC, Aphios Corporation, Moderna Inc., Sanofi Pasteur, Adjuvatis, Avanti Polar Lipids, Inc., MPV Technologies, CSL Limited, Vaxine Pty Ltd, SPI Pharma, CureVac AG, Sergeant Adjuvants, Agenus, Inc., OZ Biosciences, Adjuvants Unlimited Inc., and Adjuvants Euclid Canada Inc. are some of the key players operating in the concerned market.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
To speed up the process of nCOV vaccine development big players are collaborating with industry stakeholders. In February 2020, GSK and Coalition for Epidemic Preparedness Innovations (CEPI) collaborated to ease the out nCOV vaccine development with GSK’s vaccine adjuvant platform for other players in vaccine development. Similarly, in March 2020, iBio, a contract research organization (CRO) signed a definitive agreement with the Infectious Disease Research Institute (IDRI). The combination of iBio’s VLP antigen with the latter adjuvant expected to offer promising efficacy and safety characteristics.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: left;">
<b>Read More : <a href="https://www.polarismarketresearch.com/industry-analysis/vaccine-adjuvants-market">https://www.polarismarketresearch.com/industry-analysis/vaccine-adjuvants-market</a></b></div>
</div>
Mr. Rohit Chavanhttp://www.blogger.com/profile/08706042746893719666noreply@blogger.com0tag:blogger.com,1999:blog-8782964280890501499.post-39188525521667057882020-07-20T07:54:00.001-07:002020-07-20T07:54:23.503-07:00 Isolation Beds Market Size To Surpass USD 5.22 billion by 2027 | Polaris Market Research<div dir="ltr" style="text-align: left;" trbidi="on">
<div style="text-align: justify;">
<b>New York City, 20 Jul 2020:</b> The global<b> Isolation Beds market </b>size is expected to reach <b>USD 5.22 billion by 2027</b> according to a new study by Polaris Market Research.Isolation Beds are one of the important components in any healthcare facility. In recent times, the demand for these beds has increased significantly owing to the nature of the current COVID-19 pandemic. The Isolation Beds market is suffering from both supply and demand side. From the demand side, more than 60 to 70% of the hospitals are struggling to acquire Isolation Beds, including masks, ventilators and other medical supplies. Whereas, from the supply side due to fluctuation in supply chain manufactures are not able to meet the current booming demand due to severe shortage of raw materials.</div>
<div style="text-align: justify;">
<br /></div>
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><img alt="Isolation Bed Market" height="174" src="https://www.polarismarketresearch.com/wp-content/uploads/2020/06/Isolation-Beds-Market-Size.png" style="margin-left: auto; margin-right: auto;" width="400" /></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><b><a href="https://www.polarismarketresearch.com/industry-analysis/isolation-beds-market/request-for-sample" target="_blank">Request for sample pages </a></b></td></tr>
</tbody></table>
<div style="text-align: justify;">
With high infection rates and shortage of Isolation Beds, the government is focusing on alternate ways to increase the Isolation Beds facilities. In line with this, in April 2020, the Indian railways converted 20,000 train compartments into isolation wards. Similarly, in March 2020, Spain converted IFEMA conference hall into a hospital with 5,500 bed capacity to limit community transmission.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The factors responsible for the growth of Isolation Beds include an increase in the volume of chronic care patients, the rapid surge in COVID-19 patients, and increased preference towards home care for geriatrics. As of 23 June 2020, as per statistics published by John Hopkins University, the global cases of COVID-19 reached more than 9 million and deaths were around 471,000. The other countries more than 10,000 deaths were France (29,666), Mexico (22,584), Italy (34,657), Spain (28,324), UK (42,731), and India (13,699).</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Market participants such as Invacare Corporation, Arjo Huntleigh (part of Gentige AB), Savion Industries Ltd., Joerns Healthcare, Joh. Stiegelmeyer GmbH, LINET Group, Stryker Corporation, Span-America Medical Systems, Gendron, Inc., Paramount Bed Holdings, Hill Rom Inc., Medline Industries, and Malvestio S.P.A. are some of the key players operating in the isolation beds market.</div>
<div style="text-align: justify;">
<b><br /></b></div>
<div style="text-align: justify;">
<b>Read More : <a href="https://www.polarismarketresearch.com/industry-analysis/isolation-beds-market">https://www.polarismarketresearch.com/industry-analysis/isolation-beds-market</a></b></div>
</div>
Mr. Rohit Chavanhttp://www.blogger.com/profile/08706042746893719666noreply@blogger.com0tag:blogger.com,1999:blog-8782964280890501499.post-2110273360642702242020-07-20T07:44:00.002-07:002020-07-20T07:44:22.479-07:00Vascular Access Device Market Size To Surpass $7.72 Billion By 2027 | Polaris Market Research<div dir="ltr" style="text-align: left;" trbidi="on">
<b style="text-align: justify;">New York City, 20 Jul 2020</b><span style="text-align: justify;">: The global </span><b style="text-align: justify;">Vascular Access Device Market</b><span style="text-align: justify;"> size is expected to reach </span><b style="text-align: justify;">USD 7.72 billion by 2027 </b><span style="text-align: justify;">according to a new study by Polaris Market Research. Devices that are used to access venous irrespective of their location are known as vascular access devices (VAD). The different types of VADs include centrally inserted central catheter (CICC), peripheral intravenous catheters, and peripheral central catheter (PICC), and other implanted venous ports. VADs are inserted into peripheral or central vessels for the administration of fluids, antibiotics, parenteral nutrition, and blood sampling.</span><br />
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The selection VADs is extremely important in treating any particular medical condition to reduce the risk of catheter bound infections. Healthcare practitioners should be aware of selecting VADs with least number of the lumen and small French size to minimize infections and thrombotic complications. For instance, people suffering with chronic kidney disorder seeking central venous access should avoid placement PICC and CICC to avoid the complication of venous stenosis and deep vein thrombosis.</div>
<div style="text-align: justify;">
<br /></div>
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><img alt="Vascular access device market size" height="174" src="https://www.polarismarketresearch.com/wp-content/uploads/2020/07/Vascular-Access-Device-Market.png" style="margin-left: auto; margin-right: auto;" width="400" /></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><b><a href="https://www.polarismarketresearch.com/industry-analysis/vascular-access-device-market/request-for-sample" target="_blank">Request for sample pages </a></b></td></tr>
</tbody></table>
<div style="text-align: center;">
<br /></div>
<div style="text-align: justify;">
The factors responsible for the growth of global market are rising cases of chronic kidney disorder (CKD), increasing cases of PAD and CAD among geriatrics, and preference of patients towards minimal invasive surgeries is contributing to the worldwide demand of vascular devices. According to the statistics published by Center for Disease Control and Prevention (CDC), in 2019, more than 8.5 million U.S. citizens were suffering with peripheral artery disease (PAD). People with PAD are more susceptible to develop coronary artery disease, which could ultimately lead to strokes or cardiac arrhythmias.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Market participants such as <b>Smiths Medical, Inc., Becton Dickinson and Company, C.R. Bard, Inc., Teleflex Incorporated, B. Braun Melsungen Ag, Bluegrass Vascular Technologies, Edwards Lifesciences Corporation, Angiodynamics Inc., Biomerics, Terumo Corporation, Romsons Scientific & Surgical Pvt. Ltd, Nipro Medical Corporation, Ameco Medical, and Prodi med are some of the key players operating in the concerned market.</b> These players in the industry possess a significant share in the global market. However, these significant players face competition from local manufacturers in several countries. They adopt competitive pricing to consolidate their market share. These vendors provide cost-effective equipment with limited features and functionalities.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Read More : <a href="https://www.polarismarketresearch.com/industry-analysis/vascular-access-device-market">https://www.polarismarketresearch.com/industry-analysis/vascular-access-device-market</a></b></div>
</div>
Mr. Rohit Chavanhttp://www.blogger.com/profile/08706042746893719666noreply@blogger.com0tag:blogger.com,1999:blog-8782964280890501499.post-49152217528095447752020-07-20T07:41:00.000-07:002020-07-20T07:41:04.624-07:00Japan Cancer Vaccines Market Size To Surpass $1,470.4 Million by 2026 | Polaris Market Research<div dir="ltr" style="text-align: left;" trbidi="on">
<div style="text-align: justify;">
<b>New York City, 20 Jul 2020: </b>The<b> Japan Cancer Vaccines market</b> size is expected to reach <b>USD 1,470.4 Million by 2026</b> according to a new study by Polaris Market Research. For several years now, Japan has been experiencing a boom in the incidence of cancer patients. Cancer is one of the major causes of death in Japan. As cancer prevention, the people in Japan mainly follow their traditional low-fat diet which has proven to be effective however, there are certain limitation to this as high salt in the Japanese diet can act as a potential risk for development of stomach cancer. Though Japanese government is promoting various new ways of prevention and treatment of the disease, implementation of cancer vaccines in the healthcare regime is a must and it is necessary for the government to take steps towards usage of these vaccines in Japan.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The primary factor driving the growth of this market in Japan is the growing rate of prevalence of incidence. According to the National Cancer Registry system, in 2016, around 995,132 new patients were diagnosed with cancer of which 566,575 were men and 428,499 were women. Each year, about 10,000 Japanese women are newly diagnosed with the disease while 3,000 die from it. With growing number of patients there is a rising need for a preventive measure that could help stabilize the increasing rate of incidence. Furthermore, growing government initiatives to generate awareness amongst people, and increasing research and development activities are also fueling the growth of this market in Japan.</div>
<div style="text-align: justify;">
<br /></div>
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><img alt="Cancer Vaccines Market Size" src="https://www.polarismarketresearch.com/wp-content/uploads/2020/06/Japan-Cancer-Vaccines-Market.png" style="margin-left: auto; margin-right: auto;" /></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><a href="https://www.polarismarketresearch.com/industry-analysis/japan-cancer-vaccines-market/request-for-sample" target="_blank">Request for sample pages </a></td></tr>
</tbody></table>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
For instance, in January 2018 the University of Tokyo signed an agreement with the Kanagawa Cancer Center in Yokohama and BrightPath Biotherapeutics for development of a personalized cancer vaccine using a novel method involving the body’s immune response. Furthermore, in February 2018, Japanese Patent Office issued a decision to grant a patent covering the use of cancer vaccine technology for the treatment of a range of cancers in humans and animals. Such initiatives and research activities are with an aim of improving the cancer vaccine product line in the Japanese market and thus, fuel the growth of this regional segment.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In 2013, HPV vaccines were added to the national vaccine program in Japan. The same year, several complains were registered proving the side effects associated with cancer vaccines in Japan. This was the major reason for the suspended its recommendation and usage in Japanese industry. Before the suspension around 70% of adolescent girls received the immunization as prevention from cervical cancer. However this number dropped to less than 1% after the health ministry suspended its active recommendation after reports of side effects including muscle pain, sleep disorders, and light and sound sensitivity. Furthermore, companies also restrict from opting to manufacture cancer vaccines as it is a time consuming process with high cost of development and initial setup. These and many such factors are expected to hinder the market growth of cancer vaccines in the Japanese industry during the forecast period.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Japanese government and many local and international companies are taking initiatives to develop the cancer vaccine industry in this region. In order to promote and develop regenerative medicine and cell therapy in Japan, the Act on the Safety of Regenerative Medicine and the Revised Pharmaceutical Affairs Law was enforced in November 2014. Also, Advanced Medical Care is accepted in Japan to evaluate a medical technology at one’s own expense, together with the National Health Insurance, at institutes and hospitals approved by the MHLW. The technological intervention includes regenerative medicine and immunotherapy, the safety and efficacy of which have not been established by previous clinical studies.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Furthermore, many companies are conducting clinical trials to develop and launch innovative vaccines that could help the cancer patients. Companies such as Cytlimic, Aduro Biotech, Oncolys BioPharma, and Otsuka are some of them who have initiated many projects focusing on enhancing their cancer vaccine product line. These initiatives have attracted international funding and thus has created significant growth opportunities for established and emerging players in the global and Japanese cancer vaccines market. <b>The key players in the market include</b> Aduro BioTech, Inc., Astellas Pharma, Inc., Bristol-Myers Squibb, tella, Inc., Oncolys BioPharma Inc., CYTLIMIC, Takeda Pharamceutical, and Takara Bio among others.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: left;">
<b>Read More </b>: <a href="https://www.polarismarketresearch.com/industry-analysis/japan-cancer-vaccines-market"><b>https://www.polarismarketresearch.com/industry-analysis/japan-cancer-vaccines-market</b></a></div>
</div>
Mr. Rohit Chavanhttp://www.blogger.com/profile/08706042746893719666noreply@blogger.com0tag:blogger.com,1999:blog-8782964280890501499.post-77053849230919300832020-07-20T07:21:00.002-07:002020-07-20T07:23:32.626-07:00Face Mask Market Size To Surpass $7.22 Billion by 2026 | CAGR: 22.14% | Polaris Market Research<div dir="ltr" style="text-align: left;" trbidi="on">
<div style="text-align: justify;">
<b>New York City, 20 Jul 2020: The global Face Mask market size is expected to reach USD 7.22 billion by 2026</b> according to a new study by Polaris Market Research. The World Health Organization (WHO) has recommended to use face mask in home as well as in all healthcare institutions to successfully tackle the health challenges and infection dangers posed by COVID-19. Face mask is used for protection against respiratory infections and to create the physical barrier between nose and mouth of the wearer and potential contaminants in the immediate environment and are available in different thickness and ability to protect from contaminants. The rising cases of corona virus across the globe is expected to benefit the market over the next six years.</div>
<div style="text-align: justify;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
</div>
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><img alt="Face Mask Market" height="182" src="https://www.polarismarketresearch.com/wp-content/uploads/2020/05/Face-Mask-Market-Size.png" style="margin-left: auto; margin-right: auto;" width="400" /></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><b><a href="https://www.polarismarketresearch.com/industry-analysis/face-mask-market" target="_blank">Request for sample pages </a></b></td></tr>
</tbody></table>
<br /><br />
<div style="text-align: justify;">
Continuously increasing pollution and unhealthy working hours, growth in consumer awareness regarding airborne infections associated with the rise in outbreaks in the recent past, high consumption rate of surgical mask for personal use, increasing demand for face mask from e commerce platforms, rising standard of living, are some of the factors benefitting the market growth.<br />
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Moreover, the key players involved in the global Face Mask Market include, <b>Moldex, Shanghai Dasheng, Kimberly-Clark, BDS, Gerson, Halyard Healthcare, SAS Safety Corp., Honeywell, Irema, KOWA, 3M, McKesson, MolnlyckeHealth, CM, Sinotextiles, DACH,Te Yin, Hakugen, and Uvex among others are key players in the market</b>.. Product launch, merger & acquisition, and partnerships encompass key players’ strategies to preserve and capture the most important share of the global market.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The healthy demand for disposable designer face mask, increasing demand for face mask among the younger generation and disposable face mask among the general public are the factors expected to provide promising growth opportunities for the global market during the forecast period. However, the increasing demand for counterfeit products both in physical stores and on online platforms is expected to challenge the growth of the global market during the forecast period.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In 2020, North America region is expected to dominate the market in terms of value and volume during the forecast period. This dominance is due to the increased spending of consumers on personal care products and growing awareness regarding pathogenic infections are some of the factors benefitting the regional market growth. However, the Asia-Pacific is expected to witness the highest growth rate from 2020 to 2026. The demand for novel product line from millennial and generation X consumer groups in the region is expected to register highest growth rate during the forecast period.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Read More : <a href="https://www.polarismarketresearch.com/industry-analysis/face-mask-market">https://www.polarismarketresearch.com/industry-analysis/face-mask-market</a></b></div>
</div>
Mr. Rohit Chavanhttp://www.blogger.com/profile/08706042746893719666noreply@blogger.com0tag:blogger.com,1999:blog-8782964280890501499.post-27100856445898125102020-07-20T07:18:00.002-07:002020-07-20T07:18:45.615-07:00Hand Sanitizer Market Size worth $17.2 Billion by 2026 | Polaris Market Research<div dir="ltr" style="text-align: left;" trbidi="on">
<div style="text-align: justify;">
<b>New York City, 20 Jul 2020:</b> The global <b>hand sanitizer market size is expected to reach USD 17.2 billion by 2026 according</b> to a new study by Polaris Market Research.The market for hand sanitizers has gained a sudden momentum due to the COVID-19 pandemic which is spread across the globe. World Health Organization has already mentioned in its advisory the importance of usage of hand sanitizers during these days and due to this the governments across the globe have made it mandatory the usage, which has pushed the market for these handrubs. There has been a sudden surge in the demand for all types of sanitizer and some countries which are developing are also facing shortage. </div>
<div style="text-align: justify;">
<br /></div>
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><img alt="hand rub market" height="184" src="https://www.polarismarketresearch.com/wp-content/uploads/2020/05/Hand-Sanitizers-Market-Size.png" style="margin-left: auto; margin-right: auto;" width="400" /></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><a href="https://www.polarismarketresearch.com/industry-analysis/hand-sanitizer-market/request-for-sample" target="_blank"><b>Request for sample pages </b></a></td></tr>
</tbody></table>
<div style="text-align: justify;">
Hence many manufacturing industries are striving their best to distribute hand sanitizer in the marketplace. Governments are also encouraging its usage, thereby increasing its demand. The World Health Organization (WHO) has also recommended its usage at home, healthcare institutions as well as in all industries, offices, etc. to face the outbreak <b>COVID-19</b>. These new norms have enormously pushed the market and has gained an unprecedented traction in 2020.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The players are who helping the health care sectors are <b>Gojo Industries, Inc., Vi-Jon, Inc., Nice Pak, EO Products, Edgewell Personal Care, KAS Direct, LLC, 3M Company, Best Sanitizers, Inc., Byotrol plc, Chattem, Inc., Henkel AG & Co. KGaA, Lion Corporation, Medline Industries, Inc., Procter & Gamble Co., Reckitt Benckiser Group plc, SC Johnson & Son, Inc., Deb Group Ltd., Skinvisible, Inc., The Clorox Company, Unilever plc, Godrej Consumer Products Ltd, Zep, Inc., The Himalaya Drug Company and others across the global market</b>. The most important share hand sanitizer in the global market are launching product, marketing, acquisition to encompass the consumer to increase the selling percentages of strategies to preserve and capture the hand sanitizer market.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
These sanitizers are majorly of two types which include alcohol or non-alcohol-based sanitizer. There has been a major demand for alcohol-based hand sanitizers. These sanitizers are mainly relevant within the liquid handrub, gel-based handrub, foam-based, and spray-based hand sanitizer for killing diseases. Based on the current scenario, the government and other private institutes are also implementing sprinkler-based sanitization systems, especially in the infected areas. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
This report focuses on the upward push in the amalgamation of distribution of handrub by the means of e-commerce and hospital pharmacies. It also focuses on the trends in the healthcare industry for using the alcohol based liquid hand sanitizer to eliminate the chances of getting infected. The report analyzes on how the availability of hand sanitizer has raise the competition and price attrition of handrub.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Based on region, the global handrub industry has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America region is expected to dominate the market in terms of quantity on account of the higher number of<b> COVID-19 </b>cases and production of handrub. Moreover, Asia-Pacific is the largest producer of liquid hand sanitizer for the consumers and is expected to grow in the global market in 2020. The volume and value of these products are expected to increase due to the demand for the handrub in the region in the coming years majorly because of the pandemic. Moreover, majority of the population in the Asia Pacific region is now more aware about the benefits of the usage of handrubs and sanitizers due to the current pandemic. This would in turn benefit the market in the APAC region.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
On the basis of product type, liquid hand sanitizer has gained the popularity related to minimize the risk of the transmission of infectious disease. Handrubs are assisting the health care sectors primarily in stopping supply of such transmission diseases while maintaining contact with the patients’ or personal with each other while functionalities of the healthcare workers. Liquid hand sanitizer along with other alcohol based sanitizers and chemicals can also be used to disinfected masks, hands or the contaminated area to minimize the transmission cases of infectious diseases such as COVID-19, thus creating an opportunity for this market.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The European marketplace is projected to preserve a steady growth revenue over the forecast period. Hand sanitizer encompassed with the Himalayan Drug Company trying to make contemporary sensing in the health systems and witness to expand the adoption of using hand sanitizer in Europe, which has greatly aided to decrease the infection in the polluted places.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>Read More : <a href="https://www.polarismarketresearch.com/industry-analysis/hand-sanitizer-market" target="_blank">https://www.polarismarketresearch.com/industry-analysis/hand-sanitizer-market</a></b></div>
</div>
Mr. Rohit Chavanhttp://www.blogger.com/profile/08706042746893719666noreply@blogger.com0